Combination therapy

Through the combination therapy of epoxy croton terpene compounds and chemotherapeutic agents or radiation, the problems of side effects and drug resistance in existing cancer treatment methods have been solved, and the effects of lower doses, reduced side effects and improved treatment success rate have been achieved. It is a significant therapeutic effect in a variety of cancer types.

CN118973565APending Publication Date: 2024-11-15QBIOTICS PTY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030649.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-17
Filing Date
2023-02-17
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing cancer treatment methods have major side effects, poor applicability to patients with comorbidities, and drug resistance. The combination of existing therapies is difficult to predict, making it difficult to achieve lower doses, reduce side effects, synergistic effects and improve the success rate of treatment.

Method used

Using a combination therapy of epoxy croton terpene compounds with chemotherapeutic agents or radiation, it causes rapid hemorrhagic necrosis of tumor mass by directly destroying the tumor vasculature, and works synergistically with chemotherapeutic agents that damage DNA or chemotherapeutic agents that inhibit tumor cell growth .

Benefits of technology

The effect of lower doses, reduced side effects, increased treatment choice and improved treatment success rate was achieved, significantly improving tumor growth inhibition and survival, especially in types such as squamous cell carcinoma, adenocarcinoma and fibrosarcoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005061350990000021
    Figure BDA0005061350990000021
  • Figure BDA0005061350990000031
    Figure BDA0005061350990000031
  • Figure BDA0005061350990000041
    Figure BDA0005061350990000041
Patent Text Reader

Abstract

Provided herein are combination therapies comprising an epoxy crotonane compound (e.g., tiilanol ligand) and an irradiation or chemotherapeutic agent that is i) a DNA-disrupting chemotherapeutic agent (e.g., cis-platinum) or ii) a chemotherapeutic agent (e.g., 5-fluorouracil or adriamycin) that inhibits tumor-associated host-derived cells that support tumor cell growth and / or invasion. Also provided are pharmaceutical compositions and kits containing an epoxy crotonane compound and the chemotherapeutic agent.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to Australian Provisional Patent Application No. 2022900340 filed on February 17, 2022, the entire contents of which are incorporated herein by reference. Technical Field

[0002] The present invention relates to combination therapies comprising epoxytigliane compounds and cancer chemotherapeutic agents or irradiation. Pharmaceutical compositions and kits containing epoxytigliane compounds and cancer chemotherapeutic agents are also described. Background Art

[0003] There are many options for the treatment of cancer, including chemotherapeutic agents, irradiation, surgery, and immunostimulants. Some therapies are developed for specific types of cancer or cancers defined by specific biomarkers. Known therapies often have significant side effects and may not be suitable for some patients. For example, some tumors are inoperable, and some patients have comorbidities that reduce the effectiveness of chemotherapeutic agents or prevent the use of specific therapeutic agents due to side effects.

[0004] One option to reduce side effects, expand the treatments available to patients with comorbidities, and reduce the development of resistance to specific therapies is to use combinations of therapeutic agents. The effects of combinations of therapeutic agents can be additive, synergistic, or antagonistic, and it is not always possible to predict whether a combination is likely to be additive, synergistic, or antagonistic, or whether reducing the therapeutic dose will be effective.

[0005] There is a need for combination therapies that provide benefits to patients, such as lower dosages, reduced side effects, synergistic effects, increased therapy options, and / or improved treatment success.

[0006] Epoxytiglienone compounds have potent antitumor activity. When administered intratumorally, epoxytiglienone induces rapid hemorrhagic necrosis of tumor masses by directly destroying tumor vasculature (Boyle et al. 2014).

[0007] The present disclosure is based, at least in part, on the discovery that an epoxycrotonane compound (Compound 1) is able to synergize with cisplatin, 5-fluorouracil, doxorubicin, and irradiation in a variety of cancers, including squamous cell carcinoma, adenocarcinoma, and fibrosarcoma. Summary of the invention

[0008] In a first aspect, a method for treating a tumor is provided, the method comprising administering a combination of an epoxycrotonane compound and a second therapeutic agent; wherein the epoxycrotonane compound is a compound of formula (I):

[0009]

[0010] or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof;

[0011] in

[0012] R 1 is hydrogen or C 1-6 alkyl;

[0013] R 2 Is -OH or –OR 9 ;

[0014] R 3 Is -OH or –OR 9 ;

[0015] R 4 and R 5 are independently selected from hydrogen and C 1-6 alkyl;

[0016] R 6 is hydrogen or –R 10 ;

[0017] R 7 is hydroxyl or OR 10 ;

[0018] R 8 is hydrogen or C 1-6 alkyl;

[0019] R 9 Yes-C 1-20 Alkyl, -C 2-20 Alkenyl, -C 2-20 Alkynyl, -C(O)C 1-20 Alkyl, -C(O)C 2-20 Alkenyl, -C(O)C 2-20 Alkynyl, -C(O)cycloalkyl, -C(O)C 1-10 Alkylcycloalkyl; -C(O)C 2-10 Alkenylcycloalkyl, -C(O)C 2-10 Alkynylcycloalkyl, -C(O)aryl, -C(O)C 1-10 Alkylaryl, -C(O)C 2-10 Alkenylaryl, -C(O)C 2-10 Alkynylaryl, -C(O)C 1-10 Alkyl C(O)R 11 、-C(O)C 2-10 Alkenyl C(O)R 11 、-C(O)C 2-10 Alkynyl C(O)R 11 、-C(O)C 1-10 Alkyl CH(OR 11 )(OR11 )、-C(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-C(O)C 1-10 Alkyl SR 11 、-C(O)C 2-10 Alkenyl SR 11 、-C(O)C 2-10 Alkynyl SR 11 、-C(O)C 1-10 Alkyl C(O)OR 11 、-C(O)C 2-10 Alkenyl C(O)OR 11 、-C(O)C 2-10 Alkynyl C(O)OR 11 、-C(O)C 1-10 Alkyl C(O)SR 11 、-C(O)C 2-10 Alkenyl C(O)SR 11 、-C(O)C 2-10 Alkynyl C(O)SR 11 ,

[0020]

[0021] R 10 Yes-C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, -C(O)C 2-6 Alkynyl, -C(O)aryl, -C(O)C 1-6 Alkylaryl, -C(O)C 2-6 Alkenylaryl or -C(O)C 2-6 Alkynylaryl; and

[0022] R 11 It is hydrogen, -C 1-10 Alkyl, -C 2-10 Alkenyl, -C 2-10 Alkynyl, cycloalkyl or aryl;

[0023] wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted; and

[0024] Wherein the second therapeutic agent is selected from:

[0025] i) chemotherapeutic agents that damage DNA;

[0026] ii) chemotherapeutic agents that inhibit tumor-associated host-derived cells that support tumor cell growth and / or invasion; and

[0027] iii) Irradiation.

[0028] In another aspect, a combination of an epoxy croton terpene compound and a second therapeutic agent for treating a tumor is provided, wherein the epoxy croton terpene compound is a compound of formula (I):

[0029]

[0030] or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof;

[0031] in

[0032] R 1 is hydrogen or C 1-6 alkyl;

[0033] R 2 Is -OH or –OR 9 ;

[0034] R 3 Is -OH or –OR 9 ;

[0035] R 4 and R 5 are independently selected from hydrogen and C 1-6 alkyl;

[0036] R 6 is hydrogen or –R 10 ;

[0037] R 7 is hydroxyl or OR 10 ;

[0038] R 8 is hydrogen or C 1-6 alkyl;

[0039] R 9 Yes-C 1-20 Alkyl, -C 2-20 Alkenyl, -C 2-20 Alkynyl, -C(O)C 1-20 Alkyl, -C(O)C 2-20 Alkenyl, -C(O)C 2-20 Alkynyl, -C(O)cycloalkyl, -C(O)C 1-10 Alkylcycloalkyl; -C(O)C 2-10 Alkenylcycloalkyl, -C(O)C 2-10 Alkynylcycloalkyl, -C(O)aryl, -C(O)C1-10 Alkylaryl, -C(O)C 2-10 Alkenylaryl, -C(O)C 2-10 Alkynylaryl, -C(O)C 1-10 Alkyl C(O)R 11 、-C(O)C 2-10 Alkenyl C(O)R 11 、-C(O)C 2-10 Alkynyl C(O)R 11 、-C(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-C(O)C 1-10 Alkyl SR 11 、-C(O)C 2-10 Alkenyl SR 11 、-C(O)C 2-10 Alkynyl SR 11 、-C(O)C 1-10 Alkyl C(O)OR 11 、-C(O)C 2-10 Alkenyl C(O)OR 11 、-C(O)C 2-10 Alkynyl C(O)OR 11 、-C(O)C 1-10 Alkyl C(O)SR 11 、-C(O)C 2-10 Alkenyl C(O)SR 11 、-C(O)C 2-10 Alkynyl C(O)SR 11 ,

[0040]

[0041] R 10 Yes-C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, -C(O)C 2-6 Alkynyl, -C(O)aryl, -C(O)C 1-6 Alkylaryl, -C(O)C 2-6 Alkenylaryl or -C(O)C 2-6 Alkynylaryl; and

[0042] R 11 It is hydrogen, -C 1-10 Alkyl, -C 2-10 Alkenyl, -C 2-10 Alkynyl, cycloalkyl or aryl;

[0043] wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted; and

[0044] Wherein the second therapeutic agent is selected from:

[0045] i) chemotherapeutic agents that damage DNA;

[0046] ii) chemotherapeutic agents that inhibit tumor-associated host-derived cells that support tumor cell growth and / or invasion; and

[0047] iii) Irradiation.

[0048] In another aspect, there is provided a use of an epoxy croton terpene compound in the preparation of a first drug and a second chemotherapeutic agent in the preparation of a second drug, wherein the first drug and the second drug are used as a combination therapy for treating tumors; wherein the epoxy croton terpene compound is a compound of formula (I):

[0049]

[0050] or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof;

[0051] in

[0052] R 1 is hydrogen or C 1-6 alkyl;

[0053] R 2 Is -OH or –OR 9 ;

[0054] R 3 Is -OH or –OR 9 ;

[0055] R 4 and R 5 are independently selected from hydrogen and C 1-6 alkyl;

[0056] R 6 is hydrogen or –R 10 ;

[0057] R 7 is hydroxyl or OR 10 ;

[0058] R 8 is hydrogen or C 1-6alkyl;

[0059] R 9 Yes-C 1-20 Alkyl, -C 2-20 Alkenyl, -C 2-20 Alkynyl, -C(O)C 1-20 Alkyl, -C(O)C 2-20 Alkenyl, -C(O)C 2-20 Alkynyl, -C(O)cycloalkyl, -C(O)C 1-10 Alkylcycloalkyl; -C(O)C 2-10 Alkenylcycloalkyl, -C(O)C 2-10 Alkynylcycloalkyl, -C(O)aryl, -C(O)C 1-10 Alkylaryl, -C(O)C 2-10 Alkenylaryl, -C(O)C 2-10 Alkynylaryl, -C(O)C 1-10 Alkyl C(O)R 11 、-C(O)C 2-10 Alkenyl C(O)R 11 、-C(O)C 2-10 Alkynyl C(O)R 11 、-C(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-C(O)C 1-10 Alkyl SR 11 、-C(O)C 2-10 Alkenyl SR 11 、-C(O)C 2-10 Alkynyl SR 11 、-C(O)C 1-10 Alkyl C(O)OR 11 、-C(O)C 2-10 Alkenyl C(O)OR 11 、-C(O)C 2-10 Alkynyl C(O)OR 11 、-C(O)C 1-10 Alkyl C(O)SR 11 、-C(O)C 2-10 Alkenyl C(O)SR 11 、-C(O)C 2-10 Alkynyl C(O)SR 11 ,

[0060]

[0061] R 10 Yes-C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, -C(O)C 2-6 Alkynyl, -C(O)aryl, -C(O)C 1-6 Alkylaryl, -C(O)C 2-6 Alkenylaryl or -C(O)C 2-6 Alkynylaryl; and

[0062] R 11 It is hydrogen, -C 1-10 Alkyl, -C 2-10 Alkenyl, -C 2-10 Alkynyl, cycloalkyl or aryl;

[0063] wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted; and

[0064] Wherein the second chemotherapeutic agent is selected from:

[0065] i) chemotherapeutic agents that damage DNA; and

[0066] ii) Chemotherapeutic agents that inhibit tumor-associated host-derived cells that support tumor cell growth and / or invasion.

[0067] In another aspect, there is provided a use of an epoxy croton terpene compound in the preparation of a medicament for treating a tumor in combination therapy with irradiation; wherein the epoxy croton terpene compound is a compound of formula (I):

[0068]

[0069] or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof;

[0070] in

[0071] R 1 is hydrogen or C 1-6 alkyl;

[0072] R 2 Is -OH or –OR 9 ;

[0073] R 3 Is -OH or –OR 9 ;

[0074] R 4 and R5 are independently selected from hydrogen and C 1-6 alkyl;

[0075] R 6 is hydrogen or –R 10 ;

[0076] R 7 is hydroxyl or OR 10 ;

[0077] R 8 is hydrogen or C 1-6 alkyl;

[0078] R 9 Yes-C 1-20 Alkyl, -C 2-20 Alkenyl, -C 2-20 Alkynyl, -C(O)C 1-20 Alkyl, -C(O)C 2-20 Alkenyl, -C(O)C 2-20 Alkynyl, -C(O)cycloalkyl, -C(O)C 1-10 Alkylcycloalkyl; -C(O)C 2-10 Alkenylcycloalkyl, -C(O)C 2-10 Alkynylcycloalkyl, -C(O)aryl, -C(O)C 1-10 Alkylaryl, -C(O)C 2-10 Alkenylaryl, -C(O)C 2-10 Alkynylaryl, -C(O)C 1-10 Alkyl C(O)R 11 、-C(O)C 2-10 Alkenyl C(O)R 11 、-C(O)C 2-10 Alkynyl C(O)R 11 、-C(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-C(O)C 1-10 Alkyl SR 11 、-C(O)C 2-10 Alkenyl SR 11 、-C(O)C 2-10 Alkynyl SR 11 、-C(O)C 1-10 Alkyl C(O)OR 11 、-C(O)C2-10 Alkenyl C(O)OR 11 、-C(O)C 2-10 Alkynyl C(O)OR 11 、-C(O)C 1-10 Alkyl C(O)SR 11 、-C(O)C 2-10 Alkenyl C(O)SR 11 、-C(O)C 2-10 Alkynyl C(O)SR 11 ,

[0079]

[0080] R 10 Yes-C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, -C(O)C 2-6 Alkynyl, -C(O)aryl, -C(O)C 1-6 Alkylaryl, -C(O)C 2-6 Alkenylaryl or -C(O)C 2-6 Alkynylaryl; and

[0081] R 11 It is hydrogen, -C 1-10 Alkyl, -C 2-10 Alkenyl, -C 2-10 Alkynyl, cycloalkyl or aryl;

[0082] wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is optionally substituted. BRIEF DESCRIPTION OF THE DRAWINGS

[0083] Figure 1a Is in BALB / c Foxn1 nu Plot of the change in volume of a single SCC-15 tumor over time following treatment with a combination of intratumoral Compound 1, intraperitoneal cisplatin, and control in a xenogeneic mouse model.

[0084] Figure 1b Is in BALB / c Foxn1 nu Plot of mean SCC-15 tumor volume over time following treatment with a combination of intratumoral Compound 1, intraperitoneal cisplatin, and control in a xenogeneic mouse model.

[0085] Figure 2 Is in BALB / c Foxn1 nuPlot of Kaplan-Meier survival curves over time for SCC-15 tumors following treatment with a combination of intratumoral Compound 1, intraperitoneal cisplatin, and control in a xenogeneic mouse model.

[0086] Figure 3a is a graph of the change in volume of a single UV-13-1 tumor over time following treatment with a combination of intratumoral Compound 1, intraperitoneal cisplatin, and control in the C3H / HeNCr syngeneic mouse model.

[0087] Figure 3b is a graph of mean UV-13-1 tumor volume over time following treatment with a combination of intratumoral Compound 1, intraperitoneal cisplatin, and control in the C3H / HeNCr syngeneic mouse model.

[0088] Figure 4 is a graph of Kaplan-Meier survival curves over time for UV-13-1 tumors following treatment with a combination of intratumoral Compound 1, intraperitoneal cisplatin, and control in the C3H / HeNCr syngeneic mouse model.

[0089] Figure 5a Is in BALB / c Foxn1 nu Plot of the change in volume of a single SCC-15 tumor over time following treatment with a combination of intratumoral Compound 1, external beam irradiation, and control in a xenogeneic mouse model.

[0090] Figure 5b Is in BALB / c Foxn1 nu Plot of mean SCC-15 tumor volume over time following treatment with a combination of intratumoral Compound 1, external beam irradiation, and control in a xenogeneic mouse model.

[0091] Figure 6 Is in BALB / c Foxn1 nu Plot of Kaplan-Meier survival curves over time for SCC-15 tumors following treatment with a combination of intratumoral Compound 1, external beam irradiation, and control in a xenogeneic mouse model.

[0092] Figure 7a is a graph of the change in volume of a single MC38 tumor over time following treatment with a combination of intratumoral Compound 1, external beam irradiation, and control in a C57BL / 6 syngeneic mouse model.

[0093] Figure 7b is a graph of mean MC38 tumor volume over time following treatment with a combination of intratumoral Compound 1, external beam irradiation, and control in a C57BL / 6 syngeneic mouse model.

[0094] Figure 8is a graph of Kaplan-Meier survival curves over time for MC38 tumors following treatment with a combination of intratumoral Compound 1, intraperitoneal cisplatin, and control in a C57BL / 6 syngeneic mouse model.

[0095] Figure 9a Cell survival graph of A431 cells after simultaneous treatment with cisplatin and different concentrations of the combination of compound 1. Each data point represents the average of three different experiments.

[0096] Figure 9b Cell survival graph of SCC-15 cells after simultaneous treatment with cisplatin and different concentrations of the combination of compound 1. Each data point represents the average of three different experiments.

[0097] Fig.10a is a graph of cell survival of A431 cells after simultaneous treatment with a combination of 5-fluorouracil and different concentrations of compound 1, and each data point represents the average of three different experiments.

[0098] Fig.10b is a graph of cell survival of SCC-15 cells after simultaneous treatment with a combination of 5-fluorouracil and different concentrations of compound 1, and each data point represents the average of three different experiments.

[0099] Fig.11a is a graph of cell survival of A431 cells after simultaneous treatment with a combination of compound 1 and different concentrations of irradiation, each data point represents the average of three different experiments.

[0100] Fig.11b is a graph of cell survival of SCC-15 cells after simultaneous treatment with a combination of compound 1 and different concentrations of irradiation, each data point represents the average of three different experiments.

[0101] Fig.12 is a combined effect (Fa-CI) plot of A431 cells, showing the relationship between compound 1 and cisplatin, 5-fluorouracil and irradiation.

[0102] Fig.13 is a combined effect (Fa-CI) plot of SCC-15 cells, showing the relationship between compound 1 and cisplatin, 5-fluorouracil, and irradiation.

[0103] Fig.14a In C57BL / 6 mice, for tumors larger than 100 mm 3 Figure 3 is a graph of Kaplan-Meier survival curves over time for B16-F10-OVA tumors treated with a combination of intratumoral Compound 1 (5 μg or 10 μg) and intraperitoneal doxorubicin, as well as control.

[0104] Fig.14b is a graph of Kaplan-Meier survival curves over time following treatment with a combination of intratumoral Compound 1 (5 μg or 10 μg) and intraperitoneal doxorubicin, and control, for B16-F10-OVA tumors (overall survival) in C57BL / 6 mice.

[0105] Fig.15a In C57BL / 6 mice, for tumors larger than 100 mm 3 Kaplan-Meier survival curves over time for Lewis lung cancer (LLC) following treatment with a combination of intratumoral Compound 1 (5 μg or 10 μg) and intraperitoneal doxorubicin, and placebo.

[0106] Fig.15b is a graph of Kaplan-Meier survival curves over time for Lewis lung carcinoma (LLC) tumors (overall survival) in C57BL / 6 mice following treatment with a combination of intratumoral Compound 1 (5 μg or 10 μg) and intraperitoneal doxorubicin, and control. DETAILED DESCRIPTION

[0107] definition

[0108] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. For purposes of the present invention, the following terms are defined as follows.

[0109] The present disclosure relates to the entire contents of certain documents incorporated herein by reference. If there are any inconsistent teachings between the teachings of the present disclosure and the contents of those documents, the teachings of the present disclosure shall prevail.

[0110] It should be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms part of the common general knowledge in the art, in Australia or any other country.

[0111] Nouns without quantifiers are used herein to refer to one or more than one (ie, at least one) of the grammatical object of the reference. By way of example, "element" means one element or more than one element.

[0112] As used herein, the term "about" refers to a quantity, level, value, size, size or amount that varies by up to 25%, 20%, 15% or 10% compared to a reference quantity, level, value, size, size or amount.

[0113] As used herein, the term "and / or", such as "X and / or Y", should be understood to mean "X and Y" or "X or Y", and should be considered to provide explicit support for both meanings or for either meaning.

[0114] Throughout this specification, unless the context requires otherwise, the words "comprise, comprises, and comprising" will be understood to imply the inclusion of stated steps or elements, or groups of steps or elements, but not the exclusion of any other steps or elements, or groups of steps or elements.

[0115] Unless otherwise indicated, terms such as "first", "second", etc. are used herein merely as labels and are not intended to impose order, position, or hierarchy requirements on the items to which these terms refer. In addition, reference to a "second" item does not require or exclude the presence of lower-numbered items (e.g., "first" items) and / or higher-numbered items (e.g., "third" items).

[0116] As used herein, the phrase "at least one of..." when used with a list of items means that different combinations of one or more of the listed items may be used and only one item in the list may be required. The item may be a specific object, thing, or category. In other words, "at least one of..." means that any combination of items or multiple items in the list may be used, but all items in the list may not be required. For example, "at least one of item A, item B, and item C" may mean item A; item A and item B; item B; item A, item B, and item C; or item B and item C. In some cases, "at least one of item A, item B, and item C" may mean, for example, but not limited to, two items A, one item B, and ten items C; four items B and seven items C; or some other suitable combination.

[0117] The term "alkyl" refers to optionally substituted straight and branched chain hydrocarbon groups having 1 to 20 carbon atoms. Where appropriate, the alkyl group may have a specific number of carbon atoms, for example -C 1 -C 6 Alkyl groups include alkyl groups having 1, 2, 3, 4, 5 or 6 carbon atoms in a straight or branched arrangement. Non-limiting examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, pentyl, 2-methylbutyl, 3-methylbutyl, hexyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-ethylbutyl, 3-ethylbutyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl and pentadecyl.

[0118] The term "alkenyl" refers to an optionally substituted, unsaturated straight or branched hydrocarbon having 2 to 20 carbon atoms and having at least one double bond. Where appropriate, the alkenyl group may have a specific number of carbon atoms, such as C 2 -C 6 Alkenyl, including alkenyl having 2, 3, 4, 5 or 6 carbon atoms in a straight or branched arrangement. Non-limiting examples of alkenyl include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl and tert-butenyl, pentenyl, hexenyl, hept-1,3-diene, hexa-1,3-diene, nona-1,3,5-triene, and the like.

[0119] The term "alkynyl" refers to an optionally substituted, unsaturated straight or branched chain hydrocarbon having 2 to 20 carbon atoms and having at least one triple bond. Where appropriate, the alkynyl group may have a specific number of carbon atoms, such as C 2 -C 6 Alkynyl, which includes alkynyl groups having 2, 3, 4, 5 or 6 carbon atoms in a straight or branched arrangement. Non-limiting examples include ethynyl, propynyl, butynyl, pentynyl and hexynyl.

[0120] The terms "cycloalkyl" and "carbocycle" refer to optionally substituted saturated or unsaturated monocyclic, bicyclic or tricyclic hydrocarbon groups. Where appropriate, the cycloalkyl group may have a specific number of carbon atoms, for example, C 3 -C 6 Cycloalkyl is a carbocyclic group having 3, 4, 5 or 6 carbon atoms. Non-limiting examples may include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, and the like.

[0121] "Aryl" means a C group having up to 7 atoms in each ring. 6 -C 14 The term "aromatic" refers to a 3-membered monocyclic, bicyclic or tricyclic carbocyclic ring system in which at least one ring is aromatic. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl and biphenyl. An aryl group may contain 1 to 3 phenyl rings. If two or more aromatic rings are present, the rings may be fused together so that adjacent rings share a common bond.

[0122] Each alkyl, alkenyl, alkynyl, cycloalkyl or aryl group, whether a single entity or as part of a larger entity, may be optionally substituted with one or more optional substituents selected from the group consisting of: C 1-6 Alkyl, C 2-6 Alkenyl, C 3-6 Cycloalkyl, oxo (=O), -OH, -SH, C 1-6 Alkyl O-, C 2-6 Alkenyl O-, C 3-6 Cycloalkyl O-, C 1-6 Alkyl S-, C2-6 Alkenyl S-, C 3-6 Cycloalkyl S-, -CO 2 H, -CO 2 C 1-6 Alkyl, -NH 2 、-NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2 、-NH(phenyl), -N(phenyl) 2 、-CN、-NO 2 、-Halogen、-CF 3 、-OCF 3 、-SCF 3 , -CHF 2 、-OCHF 2 ,-SCHF 2 , -phenyl, -C 1-6 Alkylphenyl, -Ophenyl, -C(O)phenyl, -C(O)C 1-6 Examples of suitable substituents include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, vinyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methylthio, ethylthio, propylthio, isopropylthio, butylthio, hydroxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, fluorine, chlorine, bromine, iodine, cyano, nitro, -CO 2 H, -CO 2 CH 3 、-C(O)CH 3 , trifluoromethyl, trifluoromethoxy, trifluoromethylthio, difluoromethyl, difluoromethoxy, difluoromethylthio, morpholino, amino, methylamino, dimethylamino, phenyl, phenoxy, phenylcarbonyl, benzyl, and acetyl.

[0123] The epoxy croton terpene compound can be in the form of a pharmaceutically acceptable salt. However, it should be understood that non-pharmaceutically acceptable salts also fall within the scope of the present invention because they can be used as intermediates for preparing pharmaceutically acceptable salts or can be used for storage or transportation. Suitable pharmaceutically acceptable salts include, but are not limited to, pharmaceutically acceptable inorganic acid salts, such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid, boric acid, aminosulfonic acid and hydrobromic acid, or pharmaceutically acceptable organic acid salts, such as acetic acid, propionic acid, butyric acid, tartaric acid, maleic acid, hydroxymaleic acid, fumaric acid, maleic acid, citric acid, lactic acid, mucic acid, gluconic acid, benzoic acid, succinic acid, oxalic acid, phenylacetic acid, methanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, salicylic acid, aminobenzenesulfonic acid, aspartic acid, glutamic acid, edetic acid, stearic acid, palmitic acid, oleic acid, lauric acid, pantothenic acid, tannic acid, ascorbic acid and valeric acid.

[0124] Base salts include, but are not limited to, those formed with pharmaceutically acceptable cations such as sodium, potassium, lithium, calcium, magnesium, ammonium and alkylammonium.

[0125] Basic nitrogen-containing groups can be quaternized with agents such as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates, such as dimethyl sulfate and diethyl sulfate; and other agents.

[0126] It should also be recognized that epoxy croton terpene compounds can have asymmetric centers and can therefore exist in more than one stereoisomeric form. Therefore, the present invention also relates to compounds in substantially pure isomeric form at one or more asymmetric centers, for example greater than about 90% ee, for example about 95% or 97% ee or greater than 99% ee, and mixtures thereof, including racemic mixtures. Such isomers can be obtained by separation from natural sources, by asymmetric synthesis (e.g., using chiral intermediates) or by chiral resolution. The compounds of the present invention can exist in the form of geometric isomers. The present invention also relates to compounds or mixtures thereof in substantially pure cis (Z) or trans (E) forms.

[0127] The compounds of the present invention can be obtained by isolation from plants or plant parts, or by derivatization of isolated compounds, or by derivatization of related compounds. The isolation procedure and derivatization procedure can be found in WO 2007 / 070985 and WO 2014 / 169356.

[0128] The term "epoxycrotonane compound" generally refers to a compound having the following basic carbon ring structure:

[0129]

[0130] These compounds have a tricyclo[9.3.0.0]tetradecane system with a fused cyclopropane ring attached to the six-membered ring. The epoxide is fused to the 6,7-position of the seven-membered ring. Epoxytiglien-3-one compounds are typically epoxytiglien-3-one compounds. The term "epoxytiglien-3-one compound" refers to a compound having an epoxy-crotonane structure as defined above, wherein the five-membered ring has a 1,2-ene-3-one structure:

[0131]

[0132] Throughout the specification, the term "epoxycrotonane compound" is used to refer to the epoxycrotonenone compound of formula (I).

[0133] As used herein, the term "in combination with..." refers to the administration of the epoxycroton terpene compound and the second chemotherapeutic agent (e.g., cancer chemotherapeutic agent) in a single composition, or the separate administration of the second chemotherapeutic agent (e.g., cancer chemotherapeutic agent) or irradiation simultaneously or sequentially. The epoxycroton terpene compound and the second chemotherapeutic agent (e.g., cancer chemotherapeutic agent) or irradiation can be administered at different times and at different frequencies, but they exert biological effects simultaneously or in combination at overlapping times.

[0134] Treatment

[0135] The present invention relates to a method for treating tumors, which comprises the combined administration of an epoxycrotonane compound or a pharmaceutically acceptable salt thereof and a second chemotherapeutic agent or irradiation.

[0136] In some embodiments, the tumor being treated is a tumor to which the epoxy croton terpene compound can be delivered directly to the tumor in a local manner. In specific embodiments, the tumor is a skin tumor or a subcutaneous tumor or a tumor accessible from the outside of the body, such as a palpable tumor. In other embodiments, the tumor is an internal tumor. In some embodiments in which the tumor is an internally located tumor, local delivery is achieved during surgery when the tumor is exposed and the epoxy croton terpene compound can be injected. In other embodiments, the tumor is located internally and the epoxy croton terpene compound is delivered by injection guided by imaging technology (e.g., guided by endoscopic ultrasound or stereotactic imaging).

[0137] In some embodiments, the epoxycrotonane compound is delivered systemically to one or more tumors.

[0138] In some embodiments, the tumor is a benign tumor. In other embodiments, the tumor is a malignant tumor. In some embodiments, the tumor is a primary tumor, and in other embodiments, the tumor is a metastatic tumor. In some embodiments, the tumor is a skin tumor. Examples of skin tumors include seborrheic keratosis, actinic keratosis, basal cell carcinoma (BCC) (including nodular BCC, superficial BCC, invasive BCC and micronodular BCC), squamous cell carcinoma (SCC) (including SCC in situ and invasive SCC), adenocarcinoma, melanoma (including superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentigo melanoma and desmoplastic / neurotropic melanoma), sarcoma, cutaneous B cell lymphoma and cutaneous T cell lymphoma. Examples of skin and subcutaneous tumors that may be treated include angiokeratoma, pyogenic granuloma, cherry angioma, glomus tumor, angiosarcoma, karposisarcoma, Ewing's sarcoma, malignant fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, synovial sarcoma, mesenchymal sarcoma, gastrointestinal stromal sarcoma, malignant peripheral nerve sheath tumor, primitive neuroectodermal tumor, neurofibroma, Merkel cell carcinoma, dermatofibroma, fibrosarcoma, epithelioid sarcoma, and mast cell tumor.

[0139] When the tumor is an internal tumor, the internal tumor can be any tumor that is accessible by injection during surgery or by guided injection, or is a tumor that can be treated with systemic administration of epoxycrotonane, and includes tumors in the following locations: brain, lung, colon, epidermoid, squamous cell, bladder, stomach, pancreas, breast, head, neck, renal system, kidney, liver, ovary, prostate, uterus, esophagus, testicle, cervix, vagina, thyroid or skin.

[0140] In some embodiments, the tumor is a tumor of the head or neck. In some embodiments, the tumor of the head or neck is a skin tumor. In other embodiments, the tumor of the head or neck is a mucosal epithelial tumor, for example, a tumor occurring in the mucosal epithelium of the upper aerodigestive tract. In a specific embodiment, the tumor is head and neck squamous cell carcinoma (HNSCC).

[0141] In some embodiments, the tumor is a head or neck mucosal cancer, especially a mucosal squamous cell carcinoma (SCC). In some embodiments, the mucosal tumor is associated with smoking and / or drinking. In some embodiments, the tumor is a tumor of the oropharynx, especially a tumor of the tonsil or base of the tongue.

[0142] In some embodiments, the tumor is associated with human papillomavirus (HPV). In specific embodiments, the HPV-associated tumor is a mucosal SCC. HPV-associated mucosal SCCs include tumors of the oropharynx, vulva, vagina, and cervix.

[0143] In some embodiments, the tumor is a non-melanoma skin cancer (NMSC). NMSC may occur anywhere in the body. The tumor may be associated with ultraviolet solar radiation exposure, skin phenotype, immunosuppression, xeroderma pigmentosum, chemical exposure, chronic ulcers and scars, ionizing radiation, or a combination thereof. In some embodiments, the tumor is a high-risk tumor with one or more of the following characteristics: size greater than 4 cm, depth> 2 mm, presence of peripheral nerve or lymphovascular invasion, affecting the ear or lip, patient immunosuppression, and previous radiation treatment.

[0144] In some embodiments, the tumor is a squamous cell tumor (SCC), such as thyroid cancer, esophageal cancer, lung SCC, penile SCC (possibly associated with HPV) (including Bowen's disease, Erythroplasia of Queyrat, and Bowenoid papulosis), prostate cancer, vaginal cancer, cervical cancer, and bladder cancer, particularly bladder cancer associated with schistosomiasis.

[0145] In some embodiments, the tumor is a sarcoma, such as angiosarcoma, Kaposi's sarcoma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, synovial sarcoma, mesenchymal sarcoma, gastrointestinal stromal sarcoma, fibrosarcoma, or epithelioid sarcoma. In some embodiments, the sarcoma is a UV-induced fibrosarcoma.

[0146] In other embodiments, the tumor is an adenocarcinoma. Examples of adenocarcinomas include esophageal cancer, pancreatic cancer, prostate cancer, cervical cancer, gastric cancer, breast invasive ductal carcinoma, breast ductal carcinoma in situ, invasive lobular breast cancer, colon cancer, colorectal cancer, lung adenoma, bile duct cancer (choledochal carcinoma), and vaginal cancer.

[0147] Epoxycroton terpane compounds

[0148] The epoxy croton terpene compound is a 6,7-epoxy croton-1,2-ene-3-one (6,7-epoxytigli-1,2-en-3-one) compound of formula (I):

[0149]

[0150] or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof;

[0151] in

[0152] R 1 is hydrogen or C 1-6 alkyl;

[0153] R 2 Is -OH or –OR 9 ;

[0154] R 3 Is -OH or –OR 9 ;

[0155] R 4 and R 5 are independently selected from hydrogen and C 1-6 alkyl;

[0156] R 6 is hydrogen or –R 10 ;

[0157] R 7 is hydroxyl or -OR 10 ;

[0158] R 8 is hydrogen or C 1-6 alkyl;

[0159] R 9 Yes-C 1-20 Alkyl, -C 2-20 Alkenyl, -C 2-20 Alkynyl, -C(O)C 1-20 Alkyl, -C(O)C 2-20 Alkenyl, -C(O)C 2-20 Alkynyl, -C(O)cycloalkyl, -C(O)C 1-10 Alkylcycloalkyl; -C(O)C 2-10 Alkenylcycloalkyl, -C(O)C 2-10 Alkynylcycloalkyl, -C(O)aryl, -C(O)C 1-10 Alkylaryl, -C(O)C 2-10 Alkenylaryl, -C(O)C 2-10 Alkynylaryl, -C(O)C 1-10 Alkyl C(O)R 11 、-C(O)C 2-10 Alkenyl C(O)R 11 、-C(O)C 2-10 Alkynyl C(O)R 11 、-C(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkynyl CH(OR 11 )(OR 11)、-C(O)C 1-10 Alkyl SR 11 、-C(O)C 2-10 Alkenyl SR 11 、-C(O)C 2-10 Alkynyl SR 11 、-C(O)C 1-10 Alkyl C(O)OR 11 、-C(O)C 2-10 Alkenyl C(O)OR 11 、-C(O)C 2-10 Alkynyl C(O)OR 11 、-C(O)C 1-10 Alkyl C(O)SR 11 、-C(O)C 2-10 Alkenyl C(O)SR 11 、-C(O)C 2-10 Alkynyl C(O)SR 11 ,

[0160]

[0161] R 10 Yes-C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, –C(O)C 2-6 Alkynyl, -C(O)aryl, -C(O)C 1-6 Alkylaryl, -C(O)C 2-6 Alkenylaryl, -C(O)C 2-6 Alkynylaryl; and

[0162] R 11 It is hydrogen, -C 1-10 Alkyl, -C 2-10 Alkenyl, -C 2-10 Alkynyl, cycloalkyl or aryl;

[0163] wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is optionally substituted.

[0164] In some embodiments, the epoxycrotonane compound of formula (I) is a compound of formula (II):

[0165]

[0166] or its geometric isomers or stereoisomers or pharmaceutically acceptable salts; wherein R 6 , R 7 and R 9 As defined in formula (I).

[0167] In certain embodiments of formula (I) or (II), one or more of the following apply:

[0168] R 1 Yes – C 1-3 Alkyl groups, especially –CH 3 ;

[0169] R 2 Yes-OC(O)C 1-20 Alkyl, -OC(O)C 2-20 Alkenyl, -OC(O)C 2-20 Alkynyl, -OC(O)cycloalkyl, -OC(O)C 1-10 Alkylcycloalkyl; -OC(O)C 2-10 Alkenylcycloalkyl, -OC(O)C 2-10 Alkynylcycloalkyl, -OC(O)aryl, -OC(O)C 1-10 Alkylaryl, -OC(O)C 2-10 Alkenylaryl, -OC(O)C 2-10 Alkynylaryl, -OC(O)C 1-10 Alkyl C(O)R 11 、-OC(O)C 2-10 Alkenyl C(O)R 11 、-OC(O)C 2-10 Alkynyl C(O)R 11 、-OC(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-OC(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-OC(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-OC(O)C 1-10 Alkyl SR 11 、-OC(O)C 2-10 Alkenyl SR 11 、-OC(O)C 2-10 Alkynyl SR 11 、-OC(O)C 1-10 Alkyl C(O)OR 11 、-OC(O)C 2-10 Alkenyl C(O)OR 11 、-OC(O)C 2-10 Alkynyl C(O)OR 11 、-OC(O)C 1-10 Alkyl C(O)SR 11、-OC(O)C 2-10 Alkenyl C(O)SR 11 or -OC(O)C 2-10 Alkynyl C(O)SR 11 ; especially -OC(O)C 1-20 Alkyl, -OC(O)C 2-20 Alkenyl, -OC(O)C 2-20 Alkynyl, -OC(O)cycloalkyl, -OC(O)C 1-10 Alkylcycloalkyl; -OC(O)C 2-10 Alkenylcycloalkyl, -OC(O)C 2-10 Alkynylcycloalkyl or -OC(O)aryl; more particularly -OC(O)C 1-20 Alkyl, -OC(O)C 2-20 Alkenyl or -OC(O)C 2-20 Alkynyl;

[0170] R 3 Yes-OC(O)C 1-20 Alkyl, -OC(O)C 2-20 Alkenyl, -OC(O)C 2-20 Alkynyl, -OC(O)cycloalkyl, -OC(O)C 1-10 Alkylcycloalkyl; -OC(O)C 2-10 Alkenylcycloalkyl, -OC(O)C 2-10 Alkynylcycloalkyl, -OC(O)aryl, -OC(O)C 1-10 Alkylaryl, -OC(O)C 2-10 Alkenylaryl, -OC(O)C 2-10 Alkynylaryl, -OC(O)C 1-10 Alkyl C(O)R 11 、-OC(O)C 2-10 Alkenyl C(O)R 11 、-OC(O)C 2-10 Alkynyl C(O)R 11 、-OC(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-OC(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-OC(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-OC(O)C 1-10 Alkyl SR 11 、-OC(O)C 2-10 Alkenyl SR 11 、-OC(O)C2-10 Alkynyl SR 11 、-OC(O)C 1-10 Alkyl C(O)OR 11 、-OC(O)C 2-10 Alkenyl C(O)OR 11 、-OC(O)C 2-10 Alkynyl C(O)OR 11 、-OC(O)C 1-10 Alkyl C(O)SR 11 、-OC(O)C 2-10 Alkenyl C(O)SR 11 or -OC(O)C 2-10 Alkynyl C(O)SR 11 ; especially -OC(O)C 1-20 Alkyl, -OC(O)C 2-20 Alkenyl, -OC(O)C 2-20 Alkynyl, -OC(O)cycloalkyl, -OC(O)C 1-10 Alkylcycloalkyl; -OC(O)C 2-10 Alkenylcycloalkyl, -OC(O)C 2-10 Alkynylcycloalkyl or -OC(O)aryl; more particularly -OC(O)C 1-20 Alkyl, -OC(O)C 2-20 Alkenyl or -OC(O)C 2-20 Alkynyl;

[0171] R 4 and R 5 Independently selected from -C 1-3 Alkyl groups, especially –CH 3 ;

[0172] R 6 is hydrogen, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, –C(O)C 2-6 alkynyl or -C(O)aryl; especially hydrogen, -C(O)C 1-3 Alkyl, -C(O)C 2-3 Alkenyl or –C(O)C 2-3 Alkynyl, more particularly hydrogen or -C(O)CH 3 ;

[0173] R 7 It is hydroxyl, -OC(O)C 1-6 Alkyl, -OC(O)C 2-6 Alkenyl or –OC(O)C 2-6 Alkynyl, especially hydroxy, -OC(O)C 1-3 Alkyl, -OC(O)C 2-3Alkenyl or –OC(O)C 2-3 Alkynyl, more particularly hydroxy or -OC(O)CH 3 ;and

[0174] R 8 Yes-C 1-3 Alkyl groups, especially –CH 3 .

[0175] In some embodiments, the epoxycrotonane compound of formula (I) is a compound of formula (Ia):

[0176]

[0177] or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof;

[0178] in

[0179] R 1 is hydrogen or C 1-6 Alkyl (such as R 1 It is C 1-3 Alkyl groups, such as CH 3 );

[0180] R 2 Is -OH or –OR 9 ;

[0181] R 3 Is -OH or –OR 9 ;

[0182] R 4 and R 5 are independently selected from hydrogen and C 1-6 Alkyl (such as R 4 and R 5 Independently C 1-3 Alkyl groups, such as CH 3 );

[0183] R 6 is hydrogen or –R 10 ;

[0184] R 7 is hydroxyl or -OR 10 ;

[0185] R 8 is hydrogen or C 1-6 Alkyl (such as R 8 It is C 1-3 Alkyl groups, such as CH 3 );

[0186] R 9 Yes-C 1-20 Alkyl, -C2-20 Alkenyl, -C 2-20 Alkynyl, -C(O)C 1-20 Alkyl, -C(O)C 2-20 Alkenyl, -C(O)C 2-20 Alkynyl, -C(O)C 3-6 Cycloalkyl, -C(O)C 1-10 Alkyl C 3-6 Cycloalkyl; -C(O)C 2-10 Alkenyl C 3-6 Cycloalkyl, -C(O)C 2-10 Alkynyl C 3-6 Cycloalkyl, -C(O)aryl, -C(O)C 1-10 Alkylaryl, -C(O)C 2-10 Alkenylaryl, -C(O)C 2-10 Alkynylaryl, -C(O)C 1-10 Alkyl C(O)R 11 、-C(O)C 2-10 Alkenyl C(O)R 11 、-C(O)C 2-10 Alkynyl C(O)R 11 、-C(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-C(O)C 1-10 Alkyl SR 11 、-C(O)C 2-10 Alkenyl SR 11 、-C(O)C 2-10 Alkynyl SR 11 、-C(O)C 1-10 Alkyl C(O)OR 11 、-C(O)C 2-10 Alkenyl C(O)OR 11 、-C(O)C 2-10 Alkynyl C(O)OR 11 、-C(O)C 1-10 Alkyl C(O)SR 11 、-C(O)C 2-10 Alkenyl C(O)SR 11 、-C(O)C 2-10 Alkynyl C(O)SR 11 ,

[0187]

[0188] (For example, R 9 Yes-C(O)C 1-20 Alkyl or -C(O)C 2-20 alkenyl, such as crotonyl, 2-methylbutyryl, hexanoyl, myristoyl, propionyl or acetyl);

[0189] R 10 Yes-C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, -C(O)C 2-6 Alkynyl, -C(O)aryl, -C(O)C 1-6 Alkylaryl, -C(O)C 2-6 Alkenylaryl or -C(O)C 2-6 Alkynylaryl (eg R 10 Yes-C(O)C 1-3 Alkyl, such as -C(O)CH 3 );as well as

[0190] R 11 It is hydrogen, -C 1-10 Alkyl, -C 2-10 Alkenyl, -C 2-10 Alkynyl, C 3-6 In some embodiments, the epoxycrotonane compound of formula (I) is a compound of formula (Ib):

[0191]

[0192] or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof;

[0193] in

[0194] R 1 It is C 1-3 Alkyl (such as R 1 Yes CH 3 );

[0195] R 2 Yes – OR 9 ;

[0196] R 3 Yes – OR 9 ;

[0197] R 4 and R 5 Independently selected from C 1-3 alkyl;

[0198] R 6 is hydrogen or –R 10 ;

[0199] R 7 It is hydroxyl;

[0200] R 8 It is C 1-3 alkyl;

[0201] R 9 Yes-C(O)C 1-20 Alkyl or -C(O)C 2-20 Alkenyl (e.g. R 9 is crotonyl, 2-methylbutyryl, hexanoyl, myristoyl, propionyl or acetyl);

[0202] R 10 Yes-C(O)C 1-6 Alkyl (such as R 10 Yes-C(O)C 1-3 Alkyl, such as -C(O)CH 3 ).

[0203] In some embodiments, the compounds of Formula (I), (II), (Ia) and / or (Ib) have the stereochemistry shown in Formula (III):

[0204]

[0205] In some embodiments, the epoxides at the 6 and 7 positions are above the plane of the ring system. In other embodiments, the epoxides at the 6 and 7 positions are below the plane of the ring system. In some embodiments, R at the 12 position is 2 The group is S, and in other embodiments, R at position 12 2 The group is R.

[0206] In some embodiments, the epoxycrotonane compound of formula (III) is a compound of formula (IIIa):

[0207]

[0208] or a pharmaceutically acceptable salt thereof;

[0209] in

[0210] R 1 Selected from hydrogen and C 1-6 Alkyl (such as R 1 It is C 1-3 Alkyl groups, such as CH 3 );

[0211] R2 Selected from -OC(O)C 1-7 Alkyl, -OC(O)C 2-7 Alkenyl and -OC(O)C 2-7 Alkynyl (eg R 2 is -O-crotonyl, -O-2-methylbutanoyl, -O-hexanoyl, -O-myristoyl or -O-propionyl);

[0212] R 3 Selected from -OC(O)C 1-7 Alkyl, -OC(O)C 2-7 Alkenyl and -OC(O)C 2-7 Alkynyl (eg R 3 is -O-crotonyl, -O-2-methylbutyryl, -O-hexanoyl or -O-acetyl);

[0213] R 4 and R 5 are independently selected from hydrogen and C 1-6 Alkyl (such as R 4 and R 5 Independently C 1-3 Alkyl groups, such as CH 3 );

[0214] R 6 Selected from hydrogen and -C(O)C 1-6 Alkyl (such as R 6 Yes-C(O)C 1-3 Alkyl, such as -C(O)CH 3 );

[0215] R 7 is hydroxyl; and

[0216] R 8 Selected from hydrogen or C 1-6 Alkyl (such as R 8 It is C 1-3 Alkyl groups, such as CH 3 ).

[0217] In some embodiments, the epoxycrotonane compound of formula (III) is a compound of formula (IIIb):

[0218]

[0219] or a pharmaceutically acceptable salt thereof;

[0220] in

[0221] R 1 Selected from C 1-6 Alkyl (such as R 1 It is C 1-3Alkyl groups, such as CH 3 );

[0222] R 2 Selected from -OC(O)C 1-7 Alkyl and -OC(O)C 2-7 Alkenyl (e.g. R 2 is -O-crotonyl, -O-2-methylbutanoyl, -O-hexanoyl, -O-myristoyl or -O-propionyl);

[0223] R 3 Selected from -OC(O)C 1-7 Alkyl and -OC(O)C 2-7 Alkenyl (e.g. R 3 is -O-crotonyl, -O-2-methylbutyryl, -O-hexanoyl or -O-acetyl);

[0224] R 4 and R 5 Independently C 1-6 Alkyl (such as R 4 and R 5 Independently C 1-3 Alkyl groups, such as CH 3 );

[0225] R 6 Selected from hydrogen and -C(O)C 1-6 Alkyl (such as R 6 is hydrogen or -C(O)C 1-3 Alkyl, such as -C(O)CH 3 );

[0226] R 7 is hydroxyl; and

[0227] R 8 Selected from C 1-6 Alkyl (such as R 8 It is C 1-3 Alkyl groups, such as CH 3 ).

[0228] In a specific embodiment, the epoxycrotonane compound is selected from:

[0229] 12-crotonyl-13-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one (Compound 1);

[0230] 12,13-Di-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-croton-3-one (Compound 2);

[0231] 12-hexanoyl-13-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-croton-3-one (Compound 3);

[0232] 12,13-Dihexanoyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-croton-3-one (Compound 4);

[0233] 12-Myristoyl-13-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-croton-3-one (Compound 5);

[0234] 12-crotonyl-13-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13-pentahydroxy-20-acetoxy-1-crotonen-3-one (Compound 6);

[0235] 12-Myristoyl-13-acetoxy-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one (Compound 7);

[0236] 12-Propionyl-13-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one (Compound 8);

[0237] 12,13-Dicrotonyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one (Compound 9); and

[0238] 12-(2-Methylbutanoyl)-13-crotonoyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one (Compound 10).

[0239] In some embodiments, the epoxycrotonane compound is tigilanol tiglate (abbreviated as "TT"), which is (4S,5S,6R,7S,8R,9R,10S,11R,12R,13S,14R)-12-(2E)-2-methyl-2-enoyl-13((2S)-2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonitrile-3-one (also known as [(1R,2S,4R,5S,6S,10S,11R,12R,13R,14S,16R)-5,6,11-trihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-13-[(E)-2-methylbut-2-enoyl]oxy-7-oxo-3-oxapentacyclo[95.0.0 2,4 .06,10 .0 14,16 ]hexadecene-14-yl](2S)-2-methylbutanoate; chemical name calculated by Lexichem TK 2.7.0 (pubchem release 05 / 07 / 2021), having the following structure:

[0240]

[0241] Second therapeutic agent

[0242] The second therapeutic agent can be a cancer chemotherapeutic agent or radiation. In some embodiments, the second therapeutic agent is a chemotherapeutic agent. In other embodiments, the second therapeutic agent is radiation.

[0243] Without wishing to be bound by theory, it is speculated that the epoxycrotonane compounds of formula (I) may synergize with cancer therapies that damage DNA or inhibit tumor-associated host-derived cells that support tumor cell growth and / or invasion. Thus, the second therapeutic agent is a therapeutic agent that damages DNA, causes cell death, or is a therapeutic agent that kills tumor-associated host-derived cells (e.g., myeloid-derived suppressor cells (MDSCs)) that support tumor cell growth and / or invasion.

[0244] Examples of agents that damage DNA include DNA intercalators (which are substances that insert into the DNA structure of cells and bind to DNA to cause DNA damage) and DNA alkylating agents.

[0245] In some embodiments, the second therapeutic agent is a chemotherapeutic agent selected from:

[0246] i) platinum chemotherapeutics, especially cisplatin and carboplatin, more especially cisplatin (Dasari and Tchounwou, 2013; Bracci et al., 2014);

[0247] ii) DNA intercalators or topoisomerase II inhibitors, especially doxorubicin or mitoxantrone (Cheung-Ong et al., 2013);

[0248] iii) DNA alkylating agents, such as cyclophosphamide (Cheung-Ong et al., 2013; Hall and Tilby, 1992);

[0249] iv) antimetabolites, such as gemcitabine or fluorouracil, especially 5-fluorouracil (Cheung-Ong et al., 2013, Albeituni et al., 2013);

[0250] v) Vinca alkaloids, such as vincristine (Moudi et al., 2013, Mohammadgholi et al., 2013);

[0251] vi) compounds that bind to GC-rich DNA, such as bleomycin; and

[0252] vii) MDSC inhibitors, such as phosphodiesterease-5 inhibitors, such as sildenafil; amiloride or COX-2 and PEG-2 inhibitors, such as celecoxib (Albeituni et al., 2013).

[0253] In some embodiments, the second therapeutic agent is or comprises cisplatin or carboplatin. In some embodiments, the second therapeutic agent is or comprises cisplatin.

[0254] In some embodiments, the second therapeutic agent is or comprises 5-fluorouracil.

[0255] In some embodiments, the second therapeutic agent is or comprises doxorubicin. Doxorubicin is believed to damage DNA by intercalation or direct alkylation and may result in the formation of DNA double-strand breaks.

[0256] In some embodiments, the second therapeutic agent is radiation. For example, radiation can be delivered by external beam radiation therapy (in which high energy beams are aimed at the cancer site from a machine outside the body) or brachytherapy (in which the beams come from a radiation source placed next to or inside the body). At high doses, radiation therapy (or "radiotherapy") kills cancer cells by damaging their DNA and / or slowing their growth. The radiation source can be any radiation source that is commonly used for cancer radiation therapy. In some embodiments, the radiation source is cesium (e.g., cesium 137 In some embodiments, the radiation source is cobalt (e.g., cobalt 60 ).

[0257] In some embodiments, the method of treatment comprises the use of an epoxycrotonane compound (e.g., (4S, 5S, 6R, 7S, 8R, 9R, 10S, 11R, 12R, 13S, 14R)-12-(2E)-2-methyl-2-enoyl-13((2S)-2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonene-3-one) and cisplatin. This combination can be used, for example, to treat squamous cell carcinoma (SCC), including in situ SCC and invasive SCC (including UV-induced SCC).

[0258] In some embodiments, the method of treatment comprises the use of an epoxycrotonane compound (e.g., (4S, 5S, 6R, 7S, 8R, 9R, 10S, 11R, 12R, 13S, 14R)-12-(2E)-2-methyl-2-enoyl-13((2S)-2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one) and 5-fluorouracil. This combination can be used, for example, to treat squamous cell carcinoma (SCC), including in situ SCC and invasive SCC (including UV-induced SCC).

[0259] In some embodiments, the method of treatment comprises the use of an epoxycrotonane compound (e.g., (4S, 5S, 6R, 7S, 8R, 9R, 10S, 11R, 12R, 13S, 14R)-12-(2E)-2-methyl-2-enoyl-13((2S)-2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonene-3-one) and irradiation. The combination can be used, for example, to treat squamous cell carcinoma (SCC), including in situ SCC and invasive SCC (including UV-induced SCC), and adenocarcinoma, including colon adenocarcinoma.

[0260] In some embodiments, the method of treatment comprises the use of an epoxycrotonane compound (e.g., (4S, 5S, 6R, 7S, 8R, 9R, 10S, 11R, 12R, 13S, 14R)-12-(2E)-2-methyl-2-enoyl-13((2S)-2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonene-3-one) and doxorubicin. This combination can be used, for example, to treat melanoma and lung cancer.

[0261] In some embodiments, the method of treatment comprises the use of an epoxycrotonane compound (e.g., (4S,5S,6R,7S,8R,9R,10S,11R,12R,13S,14R)-12-(2E)-2-methyl-2-enoyl-13((2S)-2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one) and irradiation.

[0262] The second chemotherapeutic agent is not an immune checkpoint inhibitor.

[0263] The epoxycrotonane and the second therapeutic agent may be administered according to any suitable dosing regimen. For example, they may be administered simultaneously, sequentially or on different occasions.

[0264] In some embodiments, the treatment regimen involves administering only two components, namely an epoxy croton terpene compound and a second therapeutic agent. For example, it may involve administering an epoxy croton terpene compound and a chemotherapeutic agent that only damages DNA. Alternatively, it may include administering an epoxy croton terpene compound and a chemotherapeutic agent that only inhibits tumor-associated host-derived cells that support tumor cell growth and / or invasion. As a further alternative, the treatment regimen may involve administering only an epoxy croton terpene compound and irradiation.

[0265] In some embodiments, the treatment regimen includes administration of an epoxycrotonane compound and only one second therapeutic agent, for example, a chemotherapeutic agent that damages DNA, or a chemotherapeutic agent that inhibits tumor-associated host-derived cells that support tumor cell growth and / or invasion.

[0266] In some other embodiments, the treatment regimen includes administering an epoxycrotonane compound and two or more second therapeutic agents (e.g., two, three, four, or five second therapeutic agents), for example, it may include administering two chemotherapeutic agents that damage DNA, or two chemotherapeutic agents that inhibit tumor-associated host-derived cells that support tumor cell growth and / or invasion, or one of each of these two types of chemotherapeutic agents.

[0267] In some embodiments, the treatment regimen does not include the administration of any therapeutic agent other than the epoxycroton terpene compound and the second therapeutic agent. In some other embodiments, the treatment regimen may include the administration of an epoxycroton terpene compound, a second therapeutic agent as defined herein, and one or more (e.g., one, two, three, four, or five) additional therapeutic agents.

[0268] Composition

[0269] Although the epoxycrotane compound or a pharmaceutically acceptable salt thereof and the second chemotherapeutic agent can be administered separately, it may be more convenient to administer the epoxycrotane compound and the second chemotherapeutic agent in the form of one or more pharmaceutical compositions (each together with a pharmaceutically acceptable carrier, diluent and / or excipient).

[0270] Dosage forms and proportions for pharmaceutical uses and compositions can be readily determined by those skilled in the art.

[0271] In certain embodiments, the epoxy croton terpene compounds are formulated for direct administration onto or into the tumor being treated. In some embodiments, the epoxy croton terpene compounds are formulated for topical administration in the form of a gel, ointment, lotion, cream, or transdermal patch, which can be directly applied to the tumor being treated. In other embodiments, the epoxy croton terpene compounds are formulated for injection, particularly intratumoral injection, wherein the compound is injected into one or more locations in the tumor.

[0272] The second chemotherapeutic agent can be used in any manner capable of systemic or local delivery of molecules. In some embodiments, the second chemotherapeutic agent is conveniently delivered by injection, such as by intravenous, intraarticular, intramuscular, intradermal, subcutaneous or intraperitoneal injection. The second chemotherapeutic agent can also be formulated for local delivery by injection, such as intratumoral delivery. Pharmaceutically acceptable carriers and acceptable carriers for systemic or local administration can also be incorporated into the composition of the second chemotherapeutic agent.

[0273] In some embodiments, the epoxycroton terpene compound and the second chemotherapeutic agent are delivered separately, either simultaneously or sequentially. In other embodiments, the epoxycroton terpene compound and the second chemotherapeutic agent are delivered in a single composition, such as a single composition suitable for intratumoral delivery or a single composition formulated for systemic delivery.

[0274] In another aspect, a pharmaceutical composition is provided comprising an epoxycrotonane compound or a pharmaceutically acceptable salt thereof and a second chemotherapeutic agent, optionally together with one or more pharmaceutically acceptable carriers.

[0275] Suitably, one or more pharmaceutical compositions comprise a pharmaceutically acceptable excipient or an acceptable excipient. "Pharmaceutically acceptable excipient" refers to a solid or liquid filler, diluent or encapsulated material that can be used safely. Depending on the specific route of administration, a variety of carriers known in the art can be used. These carriers or excipients can be selected from the group comprising sugar, starch, cellulose and derivatives thereof, cyclodextrin, malt, gelatin or other gelling agents, polymers, talc, calcium sulfate, vegetable oils, synthetic oils, alcohols and / or polyols, alginic acid, phosphate buffered solution, emulsifiers, isotonic saline and pyrogen-free water.

[0276] Liquid form formulations include solutions, suspensions and emulsions, such as water or water-propylene glycol solutions. For example, parenteral injection liquid formulations can be formulated as 1,2-propylene glycol aqueous solution, dimethyl sulfoxide (DMSO), gamma cyclodextrin or 2-hydroxypropyl-β-cyclodextrin aqueous solution, saline solution or polyethylene glycol solution, with or without buffer. The preferred pH range is 3.0-4.5. Suitable buffers buffer the formulation at pH 3.5-4.5, and include but are not limited to acetate buffer and citrate buffer.

[0277] Therefore, the composition of the epoxycroton terpene compound and / or the second chemotherapeutic agent can be formulated for parenteral administration (e.g., by injection, such as a push injection or continuous infusion), and can be present in a unit dose form in an ampoule, a prefilled syringe, a small volume infusion container, or a multi-dose container to which a preservative is added. The composition can take the form of a suspension, solution, gel, or emulsion in an oily or aqueous vehicle, and can contain a preparatant (e.g., a suspending agent, a stabilizer, and / or a dispersant). Alternatively, the active ingredient can be in powder form (obtained by aseptic separation of a sterile solid or by lyophilization from a solution) for reconstitution with a suitable vehicle (e.g., sterile, pyrogen-free water) prior to use.

[0278] Pharmaceutical compositions of epoxycroton terpane compounds and / or second chemotherapeutic agents suitable for administration may be present in discrete units, such as syringes, vials, tubes or pouches, each unit containing a predetermined amount of one or more pharmaceutically active compounds or extracts of the present invention, as powders or granules, or as solutions or suspensions in aqueous liquids, cyclodextrin solutions, non-aqueous liquids, oil-in-water emulsions or water-in-oil emulsions, or as solutions or suspensions in creams or gels, or as suspensions of microparticles or nanoparticles (including but not limited to silica or polylactic acid microparticles or nanoparticles) incorporating epoxycroton terpane compounds. Such compositions may be prepared by any pharmaceutical method, but all methods include the step of combining one or more pharmaceutically active compounds of the present invention with a carrier constituting one or more necessary ingredients. In general, the composition is prepared by uniformly and intimately mixing the agent of the present invention with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, molding the product into the desired appearance.

[0279] For topical application to epidermis or other organs, epoxycroton terpene compound and / or the second chemotherapeutic agent can be formulated as gel, ointment, emulsion, paste, cream or lotion, or be formulated as transdermal patch. Suitable thickener can be used and they are added to the aqueous / alcoholic composition of compound to prepare gel. Suitable thickener or gelling agent are known in the art, such as polyvinyl carboxyl polymer carbomer 940. Ointment and emulsifiable paste can, for example, be prepared with aqueous or oily base and add suitable thickener and / or gelling agent. Lotion can be prepared with aqueous or oily base, and usually also contains one or more emulsifiers, stabilizers, dispersants, suspending agents, thickeners or coloring agents.

[0280] Formulations suitable for topical administration also include solutions or suspensions which can be applied topically as a bath or soak or spray, or which can be absorbed into a dressing.

[0281] When the second chemotherapeutic agent is a small molecule, it can be delivered by any suitable means, including oral, topical, rectal, parenteral, sublingual, buccal, intravenous, intraarticular, intramuscular, intradermal, subcutaneous, inhalation, intraocular, intraperitoneal, intracerebroventricular, transdermal, etc. as known in the pharmaceutical art.

[0282] Dosage regimen

[0283] In some embodiments, the epoxycrotonane compound is delivered in the same composition as the second chemotherapeutic agent. However, in certain embodiments, the second chemotherapeutic agent is administered in a separate composition from the epoxycrotonane compound. When the second therapeutic agent is radiation, it is of course delivered separately from the administration of the epoxycrotonane compound.

[0284] In some embodiments, the epoxycrotonane compound is administered directly to the tumor, such as by topical administration or by intratumoral injection.

[0285] In some embodiments, the epoxy croton terpene compound is applied to the tumor once. In other embodiments, the treated tumor is monitored, and if the tumor does not fully respond to the treatment, further administration of the epoxy croton terpene compound may be required. In embodiments of local treatment of tumors, the epoxy croton terpene compound can be applied multiple times over a period of time, for example once a day for a week, or once a week for 4 to 10 weeks. Those skilled in the art can determine a suitable dosage regimen by monitoring the subjects being treated, and the dosage regimen can vary according to the response to the treatment.

[0286] In certain embodiments, the epoxycrotonane compound is administered only once by intratumoral injection.

[0287] In some embodiments, the amount of epoxycrotonane compound delivered is a subtherapeutic amount.

[0288] In some embodiments, the second chemotherapeutic agent is administered at least once before, simultaneously or sequentially to the administration of the epoxy croton terpene compound. In some embodiments, the second chemotherapeutic agent is administered once before, simultaneously or after the administration of the epoxy croton terpene compound. For example, in some embodiments, the second chemotherapeutic agent is administered within 24 hours before the administration of the epoxy croton terpene compound, immediately before the administration of the epoxy croton terpene compound, simultaneously with the administration of the epoxy croton terpene compound, immediately after the administration of the epoxy croton terpene compound, or within 24 hours after the administration of the epoxy croton terpene compound, especially immediately before the administration of the epoxy croton terpene, simultaneously with the administration of the epoxy croton terpene compound, and immediately after the administration of the epoxy croton terpene. Immediately before or immediately after means that the administration of the second chemotherapeutic agent occurs less than 2 hours before or after the administration of the epoxy croton terpene compound, especially less than 1 hour and more especially less than 30 minutes.

[0289] In some embodiments, multiple doses of the second chemotherapeutic agent are administered over a period of time before or simultaneously with the administration of the epoxy croton terpene compound, and then continued after the administration of the epoxy croton terpene compound. In some embodiments, the second chemotherapeutic agent is regularly administered more than once before and after the administration of the epoxy croton terpene compound. In a specific embodiment, the second chemotherapeutic agent is administered before the administration of the epoxy croton terpene compound, sequentially or simultaneously with the administration of the epoxy croton terpene compound, and at least once after the administration of the epoxy croton terpene compound. For example, the second chemotherapeutic agent can be administered 24 hours before the administration of the epoxy croton terpene compound, and then the second chemotherapeutic agent is administered sequentially or simultaneously with the epoxy croton terpene compound, immediately before or after the administration of the epoxy croton terpene compound, and then the second chemotherapeutic agent is administered once or more within the next one to three months after the administration of the epoxy croton terpene compound, for example once a week, once every 5 days, once every 4 days, once every 3 days, once every 2 days, or once a day, especially once every 1 to 3 days, more especially once every 2 days. Administration of the second chemotherapeutic agent may be continued subsequently such that 1 to 10 doses of the second chemotherapeutic agent are administered after administration of the epoxycrotonane compound, particularly 1 to 8 doses, 1 to 6 doses, 1 to 4 doses, 1 to 3 doses or 1 to 2 doses.

[0290] In some embodiments, the epoxycroton terpene compound is administered in an effective amount. An "effective amount" means an amount necessary to at least partially achieve the desired response, such as reducing the size of a tumor or completely destroying a tumor. The amount varies depending on the health and physical condition of the individual to be treated, the taxonomic group of the individual to be treated, the formulation of the composition, the size of the tumor, the assessment of the medical condition, the second therapeutic agent used in combination therewith, and other relevant factors. It is expected that the amount will fall within a relatively wide range that can be determined by routine experiments. For example, an effective amount can be 100 mg / kg per cm2 per dose. 3 Tumor volume is about 0.1 μg to per cm 3 The tumor volume is within the range of 20 mg. The dose is preferably 100 mg per cm 3 Tumor volume ranges from 1 μg to 10 mg, for example per cm at each dose 3 In one embodiment, when the dose is administered intratumorally, the dose is in the range of 0.5 μg to 5 mg per cm 3 Tumor volume ranges from 0.01 to 1 mg, e.g. per cm 3 Tumor volume 0.1 mg to 1 mg per cm 3 Tumor volume 0.7 mg per cm 3 Tumor volume 0.1 to 0.8 mg, e.g. per cm 3Tumor volume 0.125mg to 0.7mg. In another embodiment, the dosage is within the range of 0.001mg to 20mg per dose, for example 0.005mg to 15mg per dose, especially 0.05 to 10mg per dose, more especially about 0.1 to about 5mg per dose. The dosage regimen can be adjusted to provide the best therapeutic response. For example, in some embodiments of intratumoral administration, the epoxy croton terpene compound is administered once and the treatment progress is monitored. In some embodiments, if the tumor is not completely regressed or if the tumor recurs, a second dose can be administered. In some embodiments, when the administration is topical, the topical compound formulation can be directly applied to the tumor site in the form of a gel, cream, ointment or lotion. The frequency of treatment will depend on the tumor, its size, the subject being treated, etc. In some embodiments, the topical formulation can be administered weekly until the tumor regresses. In other embodiments, the treatment can be a single treatment and the second treatment is administered only when the tumor is not completely regressed.

[0291] In some embodiments, the epoxy croton terpene compound is administered in a subtherapeutic amount. A subtherapeutic amount is an amount that is less than the amount expected to be effective when the epoxy croton terpene compound is administered alone. For example, a subtherapeutic amount can be the lower limit of the above effective amount, such as per cm 3 Tumor volume ranged from 0.1 to 0.2 mg.

[0292] The second chemotherapeutic agent can also be used in an effective amount. Similarly, it is believed that the amount of the effective second chemotherapeutic agent will depend on the subject treated, their health and physical condition, the characteristic of the second chemotherapeutic agent, the formula of the composition and the assessment of the medical condition. It is expected that the amount of the second chemotherapeutic agent will fall within a fairly wide range of amounts. The effective amount can be in the range of about 0.1ng / kg body weight to about 500mg / kg body weight, 100μg / kg body weight to 100mg / kg body weight, 1mg / kg body weight to 50mg / kg body weight, 1mg / kg body weight to 20mg / kg body weight. In another embodiment, the actual dose can be in the range of 1μg to 1g, for example, 100μg to 750mg per dose. The effective amount can be a sub-therapeutic amount when used as a monotherapy, but is an effective amount when combined with an epoxy croton terpene compound.

[0293] When the second therapeutic agent is radiation, such as external beam radiation, the radiation may be administered at least once. In some embodiments, the radiation is administered only once within 24 hours before the administration of the epoxy croton terpene compound, immediately before the administration of the epoxy croton terpene compound, immediately after the administration of the epoxy croton terpene compound, or within 24 hours after the administration of the epoxy croton terpene compound, especially immediately before or after the administration of the epoxy croton terpene compound. Immediately before or immediately after means that the radiation occurs less than 2 hours before or after the administration of the epoxy croton terpene compound, especially less than 1 hour and more especially less than 30 minutes.

[0294] In some embodiments, radiation is administered more than once, for example, radiation is administered within 24 hours prior to administration of the epoxy croton terpene compound, then administered sequentially or simultaneously with the epoxy croton terpene compound, immediately before or immediately after administration of the epoxy croton terpene compound, and then administered one or more times within the next month after administration of the epoxy croton terpene compound, for example, once a week, once every 5 days, once every 4 days, once every 3 days, once every 2 days, or once a day.

[0295] In some embodiments, the amount of radiation administered is 1 to 8 grays (Gy) per dose. In specific embodiments, the amount of radiation administered is 1 to 6 Gy, 2 to 4 Gy, or about 2 Gy per dose, for example, to deliver a total dose between 8 and 50 Gy. In some embodiments, a single irradiation is performed at a suboptimal dose, for example, a total dose between 2 and 8 Gy, particularly 2 to 4 Gy or 1 to 2 Gy.

[0296] The subject that can be treated with combination therapy is mammal, bird, aquatic animal such as fish or reptile.In some embodiments, the subject is human, experimental animal such as mouse, rat or rabbit, companion animal such as dog or cat, working animal such as horse, donkey etc., livestock animal such as cow, bull, pig, sheep, goat, deer, llama, alpaca etc., or captive wild animal, such as those in zoo or safari park, including lion, leopard, cheetah, elephant, zebra, antelope, giraffe, koala, kangaroo, and reptile such as crocodile, lizard, snake etc., bird, especially captive bird, such as budgie or canary, cockatoo, parakeet, macaw, parrot etc., or fish, especially captive fish, such as tropical fish (zebrafish, guppy, Siamese fighting fish, clown fish, A's neon characin etc.), dolphin, whale etc.In specific embodiments, the subject is human or companion animal.

[0297] In some embodiments, the subject is immunocompetent. In other embodiments, the subject is immunosuppressed or immunocompromised.

[0298] Reagent test kit

[0299] The combination of the epoxycrotonane compound and the second chemotherapeutic agent can be formulated separately and sold together in a kit or package. Each kit can contain a dosage of each compound to achieve the treatment of a tumor.

[0300] In some embodiments, the epoxy croton terpane composition is formulated for topical administration, such as in a gel, lotion, cream or ointment, or impregnated into a dressing. In other embodiments, the epoxy croton terpane compound is formulated for injection, such as intratumoral injection. In this embodiment, the epoxy croton terpane formulation can be provided as a liquid ready to be drawn into a syringe, as a powder or solid formulation that can be dissolved in a carrier prior to injection, or can be present in a kit in the form of a pre-filled syringe.

[0301] Each kit may contain one dose or multiple doses of an epoxycroton terpene compound. In one embodiment, the kit will contain a single dose of an epoxycroton terpene compound in a formulation suitable for intratumoral injection. In another embodiment, the kit will contain a topical formulation of an epoxycroton terpene compound containing multiple doses for administration to a tumor.

[0302] In some embodiments, the second chemotherapeutic agent is formulated for parenteral administration in a single bolus dose or in a multiple dose form. For example, the kit may include the second chemotherapeutic agent in a pre-filled syringe as a liquid in a vial ready for inhalation into a syringe or as a solid ready for dissolving before inhalation into a syringe. The liquid or solid formulation may be a single dose formulation or a multiple dose formulation. Alternatively, the kit may contain multiple doses of the second chemotherapeutic agent, each dose being formulated separately in a pre-filled syringe as a liquid in a vial ready for inhalation into a syringe or as a solid ready for dissolving and inhalation into a syringe.

[0303] The kit may further comprise an insert with instructions for use of each formulation, including how to prepare each dose if necessary, how to administer each dose, and when to administer each dose.

[0304] In some embodiments, the kit comprises an epoxycrotonane compound (e.g., (4S,5S,6R,7S,8R,9R,10S,11R,12R,13S,14R)-12-(2E)-2-methyl-2-enoyl-13((2S)-2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonane-3-one), which can be used, for example, with irradiation to treat tumors, such as squamous cell carcinoma (SCC), including in situ SCC and invasive SCC, and adenocarcinoma, including colon adenocarcinoma.

[0305] In some embodiments, the kit includes an epoxycrotonane compound (e.g., (4S, 5S, 6R, 7S, 8R, 9R, 10S, 11R, 12R, 13S, 14R)-12-(2E)-2-methyl-2-enoyl-13((2S)-2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonane-3-one) and cisplatin. The kit can be used, for example, to treat squamous cell carcinoma (SCC), including in situ SCC and invasive SCC.

[0306] In some embodiments, the kit includes an epoxycrotonane compound (e.g., (4S, 5S, 6R, 7S, 8R, 9R, 10S, 11R, 12R, 13S, 14R)-12-(2E)-2-methyl-2-enoyl-13((2S)-2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonane-3-one) and 5-fluorouracil. The kit can be used, for example, to treat squamous cell carcinoma (SCC), including in situ SCC and invasive SCC.

[0307] In some embodiments, the kit includes an epoxycrotonane compound (e.g., (4S, 5S, 6R, 7S, 8R, 9R, 10S, 11R, 12R, 13S, 14R)-12-(2E)-2-methyl-2-enoyl-13((2S)-2-methylbutyryl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonane-3-one) and doxorubicin. The kit can be used, for example, to treat melanoma and lung cancer.

[0308] The present disclosure is further illustrated by the following non-limiting examples.

[0309] Example

[0310] Example 1: In vivo combination of compound 1 and cisplatin

[0311] Ethical approval was obtained from the Queensland Institute of Medical Research (QIMR) Animal Ethics Committee before initiating in vivo experiments. All mice were housed in the QIMR animal facility under pathogen-free conditions and were caged with free access to filtered air, food, and water. Mice were handled and surgeries were performed using aseptic techniques in a laminar flow hood.

[0312] Before inoculation into the test mice, cancer cells were inoculated into T175 tissue culture flasks (Thermo Scientific) to increase the number of cells. Once 70-80% confluence was reached, cells were digested with trypsin and resuspended in RPMI-1640 culture medium for harvesting and cell counting using a hemocytometer. The cell volume was centrifuged and the precipitate was reconstituted in RPMI-1640 culture medium to meet the volume of the inoculation quantity required for each test mouse to be injected with 100 μL at each time at two sites. The cell suspension was stored on ice and transferred to the animal facility for injection into the test mice.

[0313] Details of the mice and cell lines used for the combination experiments are provided in Table 1. BALB / cFoxn1 nu Mice were obtained from Western Australia Animal Resources. C3H / HeNCr mice were maintained at the QIMR animal facility.

[0314] Table 1

[0315]

[0316] C3H / HeNCr mice were shaved one day before inoculation (Wahl, IL, USA). Restrained mice were inoculated bilaterally in the hind limbs by injecting 100 μL of the appropriate cell suspension into the subcutaneous space using a 27G x 1 / 2” needle (Tokyo, Japan). Mice were ear-tagged for identification. After inoculation, mice were monitored twice weekly for tumor development and health status, and once tumors developed, mice were monitored daily.

[0317] A group of thirty BALB / c Foxn1 nu A cohort of 21 C3H / HeNCr mice (each mouse had two tumors) was divided into six experimental groups, as shown in Table 2. 30 μg of compound 1 was considered to be 100 mm 3 The therapeutic dose for tumors, therefore 5 μg and 10 μg were selected as suboptimal doses.

[0318] Table 2

[0319]

[0320] The weight of each mouse was recorded before and after treatment and at the time of culling. The width and length of each tumor were measured using a 150 mm digital vernier caliper (Kinchrome, Qld, AU), and the volume of a single tumor (mm) was calculated using the following formula: 3 ):

[0321] (length x (width 2 ))÷2

[0322] When the tumor volume is expected to reach 70-100 mm 3 In the previous 24 hours, use 0.5mL U-100 insulin 29G x 1 / 2" needle administrate 2.5mg / kg cisplatin (0.5mg / mL in 0.9% saline) or the same volume of 0.9% saline intraperitoneally to the test mice. IP injection is performed by first disinfecting the anterior abdominal wall of the test mouse with an alcohol cotton swab, then grasping the dorsal skin of the test mouse and inverting the test mouse head down. Inject into the right lower abdomen using a 29G needle with the bevel facing up.

[0323] When the volume reaches 70-100mm 3 At 4 pm, the tumors of the test mice were injected IT with 50 μL of 5 μg or 10 μg of Compound 1, or 50 μL of 40% propylene glycol (PG) for control test mice.

[0324] The test mice received further IP injections of cisplatin and 0.9% saline on days 7 and 14 after the initial injection. The concentration of compound 1 was confirmed by high performance liquid chromatography (HPLC) before use.

[0325] The mice were observed daily and monitored for up to three months after treatment. Tumor volumes were recorded as described above.

[0326] When the total tumor burden per mouse reached 1000 mm 3 (if ill) and upon completion of the experiment, by inhalation of CO 2 The test mice were euthanized.

[0327] Data were analyzed to calculate mean tumor volume and standard deviation (SD) using Microsoft Excel and Prism 7. Individual and mean tumor volumes versus treatment time and Kaplan-Meier survival curves were plotted.

[0328] Heterogeneous Model

[0329] BALB / c Foxn1 nu The single SCC-15 tumor volume and average tumor volume of compound 1 and cisplatin in the mouse model were Figure 1a and 1b The Kaplan-Meier survival curve of the heterogeneous model is shown in Figure 2 shown.

[0330] BALB / c Foxn1 nuThe mouse model is an immunocompromised host that lacks a complete acquired immune system. This model allows for the evaluation of Compound 1 / cisplatin combination therapy where the host immune system is unlikely to elicit any therapeutic effect.

[0331] from Figure 1a / b and Figure 2 It can be seen that there is a clear trend in the individual tumor volume and the average tumor volume, and the Kaplan-Meier survival curves show that the combination therapy has excellent efficacy, especially in the case of higher concentrations of compound 1 (2.5 mg / kg cisplatin IP and 10 μg compound 1 IT). This combination produced a durable response, with one tumor still remaining cured at 60 days. The lower dose (5 μg) of compound 1 was not as effective as the higher dose, but still showed efficacy superior to monotherapy or no treatment.

[0332] The body weight (g) of the tested mice was used as a marker of systemic toxicity of IP cisplatin. This allows the evaluation of whether the combination therapy of sub-therapeutic concentrations of IP cisplatin shows efficacy while avoiding the common side effects associated with its administration. The results are shown in Table 3.

[0333] Table 3

[0334]

[0335] Results showed very little difference in body weight before and after treatment, but by the end of the experiment, both control and cisplatin-treated mice had gained significant weight. Although a slight loss in body weight was observed after cisplatin treatment, it was regained by the end of the experiment. While the weight gain from pre-treatment to the end of the experiment was statistically significant for both saline-treated and cisplatin-treated mice, the weight loss from pre-treatment to post-treatment with cisplatin was not statistically significant.

[0336] Syngeneic Model

[0337] The individual and average tumor volumes of UV-13-1 tumors treated with compound 1 and cisplatin in the C3H / HNCr syngeneic mouse model were Figure 3a and 3b The Kaplan-Meier survival curve of the syngeneic mouse model is shown in Figure 4 shown.

[0338] The C3H / HeNCr mouse model inoculated with UV-13-1 tumors is a syngeneic model in which the mice are immunocompetent, allowing for the evaluation of the effects of the immune system on treatment. These mice were not culled at 60 days, but were monitored regularly (weekly) up to 200 days for tumor recurrence.

[0339] Similar to the xenogeneic models, it was clear that the combination therapy of Compound 1 IT and IP cisplatin was the most effective therapy, showing greatly improved individual and mean tumor sizes as well as improved long-term survival. Figure 4 This suggests that combination therapy achieves the best duration of response.

[0340] The initial response with 10 μg of Compound 1 and saline treatment was equivalent to the combination of Compound 1 and cisplatin. However, at day 18, the efficacy of Compound 1 monotherapy declined significantly. The mean tumor size also reflected this trend. Only the combination of Compound 1 and cisplatin produced a durable tumor response, and several test mice showed no signs of recurrence at the end of the experiment. Both 5 μg and 10 μg of Compound 1 were more effective than IP cisplatin alone.

[0341] The combination results in the syngeneic model were more dramatic and durable than those in the xenogeneic model: at 60 days after combination therapy, only one tumor in the xenogeneic model remained cured, but at 200 days after treatment in the syngeneic model, nine tumors remained cured.

[0342] In the syngeneic model, weight gain was also used as a marker of cisplatin toxicity. The results are shown in Table 4.

[0343] Table 4

[0344]

[0345] The results showed that the saline control had no statistically significant weight changes during the experiment. Although the weight changes before and after treatment in the IP cisplatin group were statistically significant (p = <0.0001), the weight gain from pre-treatment to death in this group was not significant. The statistically significant weight loss from pre-treatment to post-treatment suggests that even subtherapeutic concentrations of cisplatin have some toxicity.

[0346] Summarize

[0347] A summary of survival for each treatment is shown in Table 5 .

[0348] Table 5

[0349]

[0350] Example 2: In vivo combination of Compound 1 and irradiation

[0351] Ethical approval was obtained from the Queensland Institute of Medical Research (QIMR) Animal Ethics Committee before initiating in vivo experiments. All mice were housed in the QIMR animal facility under pathogen-free conditions and were caged with free access to filtered air, food, and water. Mice were handled and surgeries were performed using aseptic techniques in a laminar flow hood.

[0352] Before inoculation into the test mice, cancer cells were inoculated into T175 tissue culture flasks (Thermo Scientific) to increase the number of cells. Once 70-80% confluence was reached, cells were digested with trypsin and resuspended in RPMI-1640 culture medium for harvesting and cell counting using a hemocytometer. The cell volume was centrifuged and the precipitate was reconstituted in RPMI-1640 culture medium to meet the volume of the inoculation quantity required for each test mouse to be injected with 100 μL at each time at two sites. The cell suspension was stored on ice and transferred to the animal facility for injection into the test mice.

[0353] Table 6 provides detailed information on the mice and cell lines used for the combination experiments. nu and C57BL / 6 mice were obtained from the Western Australian Animal Resource Center.

[0354] Table 6

[0355]

[0356] The MC38 cell line is a murine colon adenocarcinoma cell line derived from C57BL / 6 mice (Kerafast, ENH204).

[0357] C57BL / 6 mice were shaved one day before inoculation (Wahl, IL, USA). Restrained mice were inoculated bilaterally in the hind limbs by injecting 100 μL of the appropriate cell suspension into the subcutaneous space using a 27G x 1 / 2” needle (Tokyo, Japan). Mice were ear-tagged for identification. After inoculation, mice were monitored twice weekly for tumor development and health status, and once tumors developed, mice were monitored daily.

[0358] A group of thirty BALB / c Foxn1 nu A cohort of thirty C56BL / 6 mice (each mouse had two tumors) was divided into six experimental groups, as shown in Table 7. 30 μg of compound 1 was considered a therapeutic dose, and 7.5 μg was selected as the suboptimal dose.

[0359] Table 7

[0360]

[0361] The width and length of each tumor were measured using a 150 mm digital vernier caliper (Kinchrome, Qld, AU), and the volume of the individual tumor (mm) was calculated using the following formula: 3 ):

[0362] (length x (width 2 ))÷2

[0363] When the volume reaches 70-100mm 3 The tumors of the test mice were irradiated with 0, 5 or 10 Gy at 4 ℃. Each mouse was sedated by intraperitoneal injection of a combined solution of ketamine (80 mg / kg, 8 mg / mL solution, Ceva, NSW, AU) and midazolam (4 mg / kg, 0.4 mg / mL solution, Sandoz, Hozkirchen, Germany), and adequate positioning was ensured using an irradiator (Gammacel40Extractor). The mice were double-enclosed during the process of going to and from the irradiator. During irradiation, the mice were restrained with lead shielding to prevent exposure of sites other than the flank where the tumor was located. Immediately after returning to the animal facility, mice received 50 μL of 7.5 μg of compound 1 injected intratumorally (IT) using a Terumo 0.5mL U-100 insulin 29G x 1 / 2" needle, or control test mice received 50 μL of 40% propylene glycol (PG). After treatment was completed, the mice were warmed with a heating blanket, placed in lateral recumbency, and observed until they were able to move.

[0364] The mice were observed daily and monitored for up to three months after treatment. Tumor volumes were recorded as described above.

[0365] When the total tumor burden per mouse reached 1000 mm 3 (if ill) and upon completion of the experiment, by inhalation of CO 2 The test mice were euthanized.

[0366] Data were analyzed to calculate mean tumor volume and standard deviation (SD) using Microsoft Excel and Prism 7. Individual and mean tumor volumes versus treatment time and Kaplan-Meier survival curves were plotted.

[0367] Heterogeneous Model

[0368] BALB / c Foxn1 nu The individual SCC-15 tumor volumes and average tumor volumes of the mouse model treated with compound 1 and irradiation were as follows: Figure 5a and 5bThe Kaplan-Meier survival curve of the heterogeneous model is shown in Figure 6 shown.

[0369] BALB / c Foxn1 nu The mouse model is an immunocompromised host that lacks a complete acquired immune system. This model allows for the evaluation of Compound 1 / irradiation combination therapy where the host immune system is unlikely to elicit any therapeutic effect.

[0370] Figure 5a and 5b The individual and mean tumor volumes in the Figures show that Compound 1, when combined with irradiation, resulted in a significant and durable reduction in tumor size compared to the other combinations. The combination of 10 Gy and 7.5 μg IT Compound 1 provided the best results, with 5 Gy irradiation and 7.5 μg IT Compound 1 delaying tumor growth. The second best results were with either 7.5 μg IT Compound 1 or 10 Gy irradiation, both of which induced a delayed tumor response. 10 Gy irradiation induced a delayed tumor response, with mean tumor volume showing an initial steady decline, then leveling off and slightly regressing between days 20 and 25. Tumors began to recur after day 25, and mean tumor volume began to increase. There was little significant difference between treatment with 5 Gy irradiation alone and untreated controls.

[0371] Figure 5a and 5b The results in Figure 6 The Kaplan-Meier survival curves in . Figure 6 Combination treatment with Compound 1 and irradiation demonstrated a significant survival benefit over monotherapy. In this xenogeneic model, the higher dose of Compound 1 and irradiation combination had a 50% survival rate at 200 days, while the combination of 5 Gy with Compound 1 showed a 20% survival rate. The other treatments showed a gradual and steady decline in survival within the first 30 days after treatment.

[0372] Syngeneic Model

[0373] The individual and average tumor volumes of MC38 tumors treated with compound 1 and irradiation in the C57BL / 6 syngeneic mouse model were Figure 7a and 7b The Kaplan-Meier survival curve of the syngeneic mouse model is shown in Figure 8 shown.

[0374] The C57BL / 6 mouse model inoculated with MC38 tumors is a syngeneic model in which the mice are immunocompetent, allowing for the evaluation of the effects of the immune system on treatment.

[0375] In syngeneic models, the combination of compound 1 and irradiation also resulted in a significant improvement in tumor response, as shown in Figure 7a and 7b This was demonstrated by the individual and average tumor volumes in the . For each combination of Compound 1 and irradiation, two tumors remained cured 200 days after treatment. The remaining tumors all recurred and grew rapidly between 20 and 50 days after treatment. Despite the earlier recurrences, the results of the combination therapy were still far superior to other single-agent treatment regimens.

[0376] Figure 8 The Kaplan-Meier survival analysis in the 2014 study showed that compound 1 and irradiation treatment were more associated with superior survival than other treatment combinations. The two combinations of compound 1 and irradiation (5 Gy and 10 Gy) had similar long-term survival rates, each with a survival rate of 20% at the end of the experiment. Each agent used alone appeared to have similar survival rates.

[0377] Irradiation alone (either 5Gy or 10Gy) resulted in a cure rate of 0%. However, the addition of compound 1 to irradiation resulted in a significant improvement in cure rate. For the xenogeneic model, the proportion of tumors that fully responded to compound 1 and 5Gy or 10Gy irradiation was 80% and 70%, respectively, while for the syngeneic model, the proportion was 100%. The use of 7.5μg IT compound 1 alone resulted in a cure rate of 70% in both mouse models. Although the cure rate of compound 1 alone was quite high and close to that of the combination therapy, the main difference between monotherapy and combination therapy was the duration of response. Compound 1 improved the duration of therapeutic response in the xenogeneic model when combined with 5Gy or 10Gy irradiation, extending it by at least 4.6 times (11 days vs 51.5 and 111 days), and by at least 8.7 times (6.2 days vs 64.6 and 65.9 days) for the syngeneic model.

[0378] The median survival for each treatment is shown in Table 8.

[0379] Table 8

[0380]

[0381] Example 3: In vitro experiments with compound 1 and chemical irradiation

[0382] Cell lines were studied in in vitro experiments to evaluate the combined effects of Compound 1 with cisplatin, 5-fluorouracil and irradiation. The cell lines are given in Table 9 and include one skin cell line and one oropharyngeal mucosal cell line.

[0383] Table 9

[0384]

[0385] Cell culture

[0386] The samples were kept at 37°C, 5% CO2 and 95% humidity (Heracell Vios 160i CO 2 Incubator; ThermoScientific, Massachusetts, USA), cells were cultured in Roswell Park Memorial Institute (RPMI-1640; CSL Biosciences, Parkville, Victoria, Australia) medium containing 10% (v / v) fetal calf serum (FCS, CSL Biosciences), 100 μg / mL streptomycin and 60 μg / mL penicillin (CSL Biosciences), 1 mM pyruvate, 0.2 mM nicotinamide, and 3 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES). Cell line confluence was assessed twice a week, and if it approached 90%, the medium was removed for passage, and then replaced with phosphate-buffered saline (PBS, 137 mM NaCl, 6.5 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , pH 7.4, QIMR Media Services) and treated with 0.25% (v / v) trypsin (Invitrogen, CA, USA) and 3.8% (v / v) versine in Dulbecco's salt solution (QIMR Media Services) to allow cell lifting. An appropriate volume of cells (ratio of 1:5 to 1:10) was removed and the residue was re-incubated in new RPMI-1640 / FCS.

[0387] Cell lines were authenticated by short tandem repeat (STR) profiling and mycoplasma testing performed by the QIMR analytical facility.

[0388] The number of cells removed during passaging was determined using a hemacytometer (Fuchs Rosenthal Dark Lines; Hirschmann Laboratories, Eberstadt, Germany). Cells were seeded at 3000 cells / well in 100 μL of culture medium in flat-bottomed 96-well cell culture plates (Corning Incorporated, New York, USA). Cells were incubated for 24 hours before treatment to ensure plate attachment.

[0389] Single agent exposure

[0390] Each cell line was exposed to a range of doses of compound 1 (20 μg / mL in 100% ethanol), cisplatin (50 μM stock solution in 0.9% saline, Sigma Aldrich, Missouri, USA), 5-fluorouracil (5-FU, 50 μM stock solution in dimethyl sulfoxide (DMSO, Sigma Aldrich)) and irradiation. The concentration of compound 1 was confirmed by HPLC before use. Table 10 provides the dose range.

[0391] Table 10

[0392] Pharmacy Dosage Range Compound 1 0-500μM Cisplatin 0-200μM 5-Fluorouracil 0-200μM Irradiation 0-8Gy

[0393] For each of compound 1, cisplatin and 5-FU, the medium in the top row of the 96-well plate was aspirated, and then 200 μL of each drug stock solution was applied to RPMI-1640 medium to prepare the maximum required concentration. Then a one-half dilution was performed on the plate, leaving the last row as an untreated control. Each cell line has an ethanol control, which is applied in a similar manner to each drug compound. After 4, 6 or 24 hours, the drug was washed off with PBS and 100 μL of new RPMI-1640 medium was applied.

[0394] Each cell line was exposed to 0-8 Gy of cesium 137 (Gammacell 40 Exactor Theratronics, Ontario, Canada) at a rate of 1 Gy / min with 2 Gy intervals. The medium was changed immediately after treatment.

[0395] Each cell line was treated with each agent in triplicate, and the data from the three experiments were averaged.

[0396] Combined exposure

[0397] Cell lines were exposed to combinations of Compound 1 and other agents at doses ranging from 1:1 to 1:1 as shown in Table 11. Single agent experiments demonstrated that these doses resulted in minor cell death ( <IC 50 ) dosage.

[0398] Table 11

[0399]

[0400] Combination experiments between Compound 1 and cisplatin or 5-FU were performed using different administration time courses. To evaluate the effect of administration time course on therapeutic efficacy, each cell line was exposed to Compound 1 24 hours before, simultaneously and 24 hours after treatment with cisplatin or 5-FU.

[0401] Cell lines treated with a combination of Compound 1 and irradiation were first treated with the assigned irradiation duration and then immediately treated with Compound 1. For single agent experiments, wells included no treatment and ethanol treatment controls. After treatment, cells were incubated for 4 hours and then washed with PBS and the medium was replaced.

[0402] Sulforhodamine B proliferation assay

[0403] After the treated cells were incubated for 5-7 days, cell survival was determined using the sulforhodamine B (SRB) proliferation assay. The assay quantitatively evaluates the degree of protein staining as a surrogate marker for cell growth. The cells were washed with PBS and then fixed with methylated alcohol (Chem Supply, South Australia) for at least five minutes. After fixation, the methylated alcohol was removed, and the cells were gently washed with water again, and then stained with 50 μL / well of 0.4% SRB solution (Sigma Aldrich) in 1% acetic acid for 60 minutes. The solution was poured out and the cells were quickly washed twice with 1% acetic acid. The assay was completed by adding 100 μL 10mM Tris alkali (no buffer, pH>9, Invitrogen) to each well. The absorbance was measured at 564nm under stirring for 5 seconds using an enzyme-linked immunosorbent assay (ELISA) reader (VERSA max microplate reader, Molecular Devices, California, the United States). As a percentage of the absorbance of the control wells, a graph of cell survival relative to dose was drawn.

[0404] Statistical analysis

[0405] Data were analyzed using Microsoft Excel (2016, Prism (version 7.0, Graphpad software 2016) and Combusyn (version 1.0, Chou & Martin 2005). Means, standard deviations, and Chou-Talalay combination indexes (CI) (Chou (2010)) were determined and used to detect any significant differences between the control and test combinations and to assess the relationship between Compound 1 and chemoradiotherapy.

[0406] The Chou-Talalay combination theorem is a statistical method by which the effect of combining multiple agents can be quantified by generating a number relative to 1. The combined effect (CI-Fa) diagram graphically describes the combination index of a series of drug concentrations. The data points that fall below the line (the line represents a combination index of 1) indicate that there is a synergistic relationship. The benefit of the CI-Fa diagram is that it shows the trend of a series of effect levels. In the setting of this embodiment, the x-axis or effect (Fa) is directly related to cell survival. For example, an effect (Fa) of 0.1 is consistent with 10% cell survival. Software program Combusyn is used for analysis.

[0407] result

[0408] Single agent

[0409] The IC of cisplatin alone in both cell lines was 50 All of them were between 3.125 μM and 6.25 μM. SCC-15 was closer to the lower limit, while A431 was slightly more resistant and had an IC 50 Closer to the upper limit.

[0410] With a 4-hour exposure time, the IC of compound 1 alone was 50 Between 62.5 and 200 μM, SCC-15 was closer to the lower limit, and A431 was slightly more resistant and closer to the upper limit.

[0411] The IC of 5-FU alone in both cell lines was 50 A431 is slightly more sensitive and closer to the lower limit, while SCC-15 is slightly more resistant and has an IC 50 Closer to the upper limit.

[0412] Exposure to increasing concentrations of irradiation resulted in a linear decrease in cell viability in both cell lines, with IC 50 Both are about 4Gy.

[0413] As for single agent experiments, cell lines were maintained in culture before final transfer to 96-well plates. Treatments for combination experiments involved first exposing cells to cisplatin, 5-FU, or irradiation, followed by immediate 4-hour treatment with five different concentrations of compound 1. After 7 days of incubation, cell survival was determined relative to untreated controls using the SRB assay.

[0414] combination

[0415] In A431 cells, the combination of compound 1 and cisplatin increased cell survival as Figure 9a Clearly, the addition of compound 1 to cisplatin at any concentration resulted in a significant increase in cell death compared to cisplatin alone. 50 Approximately equal to or less than 1.75 μM. Except for 200 μM, there was little difference in efficacy between most concentrations of Compound 1.

[0416] In SCC-15 cells, the combination of compound 1 and cisplatin increased cell survival as Figure 9b Clearly, adding compound 1 to any concentration of cisplatin resulted in a significant increase in cell death compared to when cisplatin was used alone. 50 Approximately equal to or less than 1.75μM.

[0417] In conclusion, the combination treatment of cisplatin and compound 1 showed a trend such that an increase in cisplatin concentration led to a concomitant decrease in cell survival in both cell lines, regardless of the concentration of compound 1. The addition of compound 1, even at very low concentrations, led to a decrease in cell survival compared to those cells exposed to cisplatin alone. For both cell lines, the IC of the combination was significantly higher than that of the single agents alone. 50 Both decreased.

[0418] In A431 cells, the combination of compound 1 and 5-FU increased cell survival as Fig.10a As shown. Clearly, the addition of compound 1 to 5-FU at any concentration resulted in a significant increase in cell death compared to 5-FU alone. IC 50 Approximately equal to or less than 1.56μM.

[0419] In SCC-15 cells, the combination of compound 1 and 5-FU increased cell survival as Fig.10b As shown. Clearly, the addition of compound 1 to 5-FU at any concentration resulted in a significant increase in cell death compared to cisplatin alone. 50 Approximately equal to or less than 12.5 μM.

[0420] In summary, A431 cells and SCC-15 cells exhibited similar responses, with the addition of 5-FU and Compound 1 resulting in decreased cell survival.

[0421] In A431 cells, the combination of compound 1 and irradiation increased cell survival as Fig.11a Clearly, the addition of Compound 1 to irradiation at any concentration resulted in a significant increase in cell death compared to Compound 1 alone.

[0422] In SCC-15 cells, the combination of compound 1 and irradiation increased cell survival as Fig.11b As shown. Exposure to compound 1 and irradiation resulted in a significant decrease in cell survival. The combination was superior to compound 1 alone. Increasing irradiation exposure did not significantly improve efficacy.

[0423] IC of the combination of compound 1 and irradiation for A431 cells 50 ranged from 0 to 6.26 μM for 50% TNF-α and from 0 to 1.56 μM for SCC-15 cells.

[0424] Order of application

[0425] For the combination therapy of Compound 1 and cisplatin, there was little difference in administering Compound 1 24 hours before or 24 hours after cisplatin in A431 cells. However, concurrent therapy significantly improved efficacy compared to Compound 1 at all concentrations.

[0426] For the combination therapy of Compound 1 and cisplatin, there was little difference in the administration of Compound 1 24 h before or 24 h after or simultaneously with cisplatin in SCC-15 cells.

[0427] There were some differences in efficacy for the combination therapy of Compound 1 and 5-FU in A431 cells. Concurrent therapy resulted in the greatest cell death across the entire concentration range of Compound 1. Pretreatment with Compound 1 was the second most effective, with cell survival approaching that of concurrent treatment with higher concentrations of 5-FU.

[0428] For the combination therapy of Compound 1 and 5-FU, there was little difference in administering Compound 1 24 hours before or after 5-FU or simultaneously in SCC-15 cells.

[0429] Combination Effect

[0430] The combined effects on A431 cells are shown in Fig.12 and the IC of compound 1 at each concentration 50 The combination index is shown in Table 12.

[0431] Table 12

[0432]

[0433] Using the Chou-Talalay combination index method, these results indicate that compound 1 has a synergistic relationship with cisplatin, 5-FU, and irradiation in A431 cells. All data points combined have an index of <1.

[0434] The combined effects on SCC-15 cells are shown in Fig.13 and the IC of compound 1 at each concentration 50 The combination index is shown in Table 13.

[0435] Table 13

[0436]

[0437] Using the Chou-Talalay combination index method, the results of SCC-15 cells showed that compound 1 had synergistic relationships with cisplatin, 5-FU, and irradiation at low concentrations, and synergistic relationships at all concentrations when combined with 5-FU. However, some combination indices of compound 1 and irradiation were consistent with antagonism (CI>1).

[0438] Example 4: Evaluation of the efficacy of Compound 1 combined with chemotherapy in a mouse cancer model

[0439] This example evaluates the effects of the chemotherapeutic agent doxorubicin combined with Compound 1 on mouse cancer models, specifically melanoma and lung cancer.

[0440] Method Description

[0441] Cell lines

[0442] B16-F10-OVA (B16-F10 mouse melanoma cell line overexpressing chicken ovalbumin) was cultured in RPMI-1640 medium supplemented with 10% FCS (complete medium) and 3 mM HEPES. LLC (Lewis lung carcinoma) cells were cultured in DMEM (Gibco) medium supplemented with 10% FCS. Both cell lines were maintained at 37°C, 5% CO 2 Routine mycoplasma testing was evaluated using Myco-Alert (Lonza) and the results were always negative.

[0443] Animal experiments

[0444] C57BL / 6 mice were purchased from the Animal Resources Centre (ARC), Murdoch, Western Australia. All animal surgical procedures were approved by the QIMR Berghofer Animal Ethics Committee in accordance with NHMRC guidelines (Australian Code for the Care and Use of Animals for Scientific Purposes, 8th edition, 2013; National Health and Medical Research Council of Australia), approval number A2109-621. All mice were housed in a specific pathogen-free (SPF) facility with a 12-h light / dark cycle and continuous access to food and water.

[0445] Doxorubicin combination therapy

[0446] C57BL / 6 mice (6-7 weeks old) were injected subcutaneously (sc) in the bilateral flanks with B16-F10-OVA mouse melanoma cells (2 × 10 5 cells in 50 μl) or LLC mouse lung cancer cells (5×10 5 cells in 50 μl). Allow the tumor to grow to approximately 75-100 mm 3. Mice were then treated intraperitoneally with doxorubicin in saline (3 mg / kg; 60 μg / dose, saline as vehicle). The next day, tumors were injected intratumorally with vehicle (40% PG / 30 mM acetate) or 5 or 10 μg of compound 1 (50 μl of 100 μg / ml [5 μg] or 50 μl of 200 μg / ml [10 μg]) in 40% PG / 30 mM acetate (pH 4.30) as previously published (Cullen et al., 2021). Chemotherapeutic treatment was repeated 7 and 14 days later, respectively. For the B16-F10-OVA model, 5 mice per group (10 tumors) were used for repeated experiments (two experiments, 10 mice per group, a total of 20 tumors). For the LLC tumor model, 5 mice per group were used for a single experiment (10 tumors).

[0447] Record the volume using a digital caliper and express it in mm according to the formula A × b × b × 0.5 3 , where A = tumor length and b = measured tumor width. Mice were also assessed for clinical signs of distress during the experiment using an approved clinical scoring form. Mice were evaluated for clinical distress when an unacceptable clinical score (>6) was reached or when the cumulative tumor burden exceeded 1,000 mm 3 All mice whose tumors were ablated in the above experimental protocol were monitored for an additional 2 months to confirm cure or tumor recurrence / metastasis. 2 Mice were humanely euthanized by asphyxiation.

[0448] result

[0449] B16-F10-OVA ( Fig.14a and 14b ) tumors had no effect on tumor growth. As expected, treatment with 5 μg or 10 μg of Compound 1 slowed tumor growth and prolonged overall survival compared to vehicle alone (p<0.0001, Fig.14b (not shown). In addition, in the B16-F10-OVA model, combination therapy of doxorubicin and 10 μg Compound 1 had an effect on tumor growth, prolonging the time to the experimental endpoint compared to doxorubicin alone, while the combination of 10 μg Compound 1 and saline vehicle prolonged to a lesser extent. A total of 7 / 20 tumors were completely ablated in the doxorubicin / 10 μg Compound 1 group, compared to 4 / 20 tumors in the saline / 10 μg Compound 1 group.

[0450] LLC in C57BL / 6 mice was treated with intraperitoneal doxorubicin or saline combined with intralesional injection of 40% PG / 30 mM acetate. Fig.15a and 15b ) tumors had a minor effect on slowing tumor growth and prolonging survival. Similarly, treatment with 5 μg or 10 μg of compound 1 slowed tumor growth and prolonged overall survival compared with vehicle alone (p<0.0001, Fig.15b (not shown). In addition, in the LLC model, doxorubicin combined with 10 μg of Compound 1 had an effect on tumor growth, with no tumor growth in 3 / 10 cases. This resulted in a prolonged time to the experimental endpoint compared to doxorubicin alone, and to a lesser extent with the combination of 10 μg of Compound 1 and saline vehicle.

[0451] discuss

[0452] Combination therapy of doxorubicin and 10 μg of Compound 1 was effective in slowing tumor growth and prolonging overall survival in C57BL / 6 mice bearing B16-F10-OVA or LLC tumors.

[0453] Those skilled in the art will appreciate that, without departing from the broad general scope of the present disclosure, various changes and / or modifications may be made to the above embodiments. Therefore, the present application embodiments are considered in all aspects to be illustrative and not restrictive.

[0454] References

[0455] Sabrin Husein Albeituni, Chuanlin Ding and Jun Yan: Hampering theImmune Suppressors: Therapeutic Targeting of Myeloid-Derived Suppressor Cells (MDSC) in Cancer. Cancer J. 2013; 19(6): 490-501.

[0456] Boyle GM, D'Souza MM, Pierce CJ, Adams RA, Cantor AS, Johns JP, Maslovskaya L, Gordon VA, Reddell PW, Parsons PG. Intra-Lesional Injection of the Novel PKCActivator EBC-46 Rapidly Ablates Tumors in Mouse Models. PLoS One 9(10):e108887.

[0457] https: / / doi.org / 10.1371 / journal.pone.0108887.

[0458] L Bracci,G Schiavoni,A Sistigu and F Belardelli.Immune-basedmechanisms of cytotoxic chemotherapy:implications for the design of novel andrationale-based combined treatments against cancer.Cell Death andDifferentiation(2014)21,15-25.

[0459] Chou TC,Drug combination studies and their synergy quantificationusing the Chou-Talalay method.2010,Cancer Research,70:440-446.

[0460] Kahlin Cheung-Ong,’Guri Giaever, Corey Nislow DNA-Damaging Agents inCancer Chemotherapy:Serendipity and Chemical Biology.Chemistry and Biology 20(5),648-659,2013.

[0461] Shaloam Dasari and Paul Bernard Tchounwou.Cisplatin in cancertherapy:molecular mechanisms of action.Eur J Pharmacol.2014 Oct 5;740:364-378.

[0462] Hall AG,Tilby MJ.Mechanisms of action of,and modes of resistance to,alkylating agents used in the treatment of haematological malignancies.BloodReviews.(1992)6(3):163-73.

[0463] Azadeh Mohammadgholi,Azra Rabbani-Chadegani,and Sodabeh FallahMechanism of the Interaction of Plant Alkaloid Vincristine with DNA andChromatin:Spectroscopic Study.DNA Cell Biol.2013 May;32(5):228-235.

[0464] Maryam Moudi,Rusea Go,Christina Yong Seok Yien,and Mohd.Nazre.VincaAlkaloids.Int J Prev Med.2013 Nov;4(11):1231-1235.

[0465] Cullen JK,Boyle GM,Yap PY,Elmlinger S,Simmons JL,Broit N,Johns J,Ferguson B,Maslovskaya LA,Savchenko AI,Mirzayans PM,Porzelle A,Bernhardt PV,Gordon VA,Reddell PW,Pagani A,Appendino G,Parsons PG,Williams CM.Activationof PKC supports the anticancer activity of tigilanol tiglate and relatedepoxytiglianes.Sci Rep.2021 Jan 8;11(1):207.doi:10.1038 / s41598-020-80397-9.PMID:33420238.

Claims

1. A method for treating a tumor, the method comprising administering a combination of an epoxy croton terpene compound and a second therapeutic agent; wherein the epoxy croton terpene compound is a compound of formula (I): or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof; in R 1 is hydrogen or C 1-6 alkyl; R 2 Is -OH or –OR 9 ; R 3 Is -OH or –OR 9 ; R 4 and R 5 are independently selected from hydrogen and C 1-6 alkyl; R 6 is hydrogen or –R 10 ; R 7 is hydroxyl or OR 10 ; R 8 is hydrogen or C 1-6 alkyl; R 9 Yes-C 1-20 Alkyl, -C 2-20 Alkenyl, -C 2-20 Alkynyl, -C(O)C 1-20 Alkyl, -C(O)C 2-20 Alkenyl, -C(O)C 2-20 Alkynyl, -C(O)cycloalkyl, -C(O)C 1-10 Alkylcycloalkyl; -C(O)C 2-10 Alkenylcycloalkyl, -C(O)C 2-10 Alkynylcycloalkyl, -C(O)aryl, -C(O)C 1-10 Alkylaryl, -C(O)C 2-10 Alkenylaryl, -C(O)C 2-10 Alkynylaryl, -C(O)C 1-10 Alkyl C(O)R 11 、-C(O)C 2-10 Alkenyl C(O)R 11 、-C(O)C 2-10 Alkynyl C(O)R 11 、-C(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-C(O)C 1-10 Alkyl SR 11 、-C(O)C 2-10 Alkenyl SR 11 、-C(O)C 2-10 Alkynyl SR 11 、-C(O)C 1-10 Alkyl C(O)OR 11 、-C(O)C 2-10 Alkenyl C(O)OR 11 、-C(O)C 2-10 Alkynyl C(O)OR 11 、-C(O)C 1-10 Alkyl C(O)SR 11 、-C(O)C 2-10 Alkenyl C(O)SR 11 、-C(O)C 2-10 Alkynyl C(O)SR 11 , R 10 Yes-C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, -C(O)C 2-6 Alkynyl, -C(O)aryl, -C(O)C 1-6 Alkylaryl, -C(O)C 2-6 Alkenylaryl or -C(O)C 2-6 Alkynylaryl; and R 11 It is hydrogen, -C 1-10 Alkyl, -C 2-10 Alkenyl, -C 2-10 Alkynyl, cycloalkyl or aryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted; and wherein the second therapeutic agent is selected from: i) chemotherapeutic agents that damage DNA; ii) chemotherapeutic agents that inhibit tumor-associated host-derived cells that support tumor cell growth and / or invasion; and iii) Irradiation.

2. The method of claim 1, wherein the epoxycrotonane compound is administered topically to the tumor.

3. The method of claim 2, wherein the local administration is performed by intratumoral injection.

4. The method of any one of claims 1 to 3, wherein the second therapeutic agent is a DNA damaging chemotherapeutic agent.

5. The method of claim 4, wherein the chemotherapeutic agent is selected from a platinum chemotherapeutic agent, a DNA intercalating agent, a DNA alkylating agent, an antimetabolite, or a compound that binds to GC-rich DNA.

6. The method of any one of claims 1 to 3, wherein the second therapeutic agent is a chemotherapeutic agent that inhibits tumor-associated host-derived cells that support tumor cell growth and / or invasion.

7. The method of claim 6, wherein the chemotherapeutic agent is a vinca alkaloid, an antimetabolite, a phosphodiesterase 5 inhibitor, amiloride, a COX-2 inhibitor, or a PEG-2 inhibitor.

8. The method of any one of claims 1 to 3, wherein the second therapeutic agent is radiation.

9. The method according to any one of claims 1 to 8, wherein in the epoxycrotonane compound of formula (I), one or more of the following applies: i)R 1 Yes – CH 3 ; ii) R 2 and R 3 Independently selected from -OC(O)C 1-20 Alkyl, -OC(O)C 2-20 Alkenyl, -OC(O)C 2-20 Alkynyl, -OC(O)cycloalkyl, -OC(O)C 1-10 Alkylcycloalkyl; -OC(O)C 2-10 Alkenylcycloalkyl, -OC(O)C 2-10 Alkynylcycloalkyl, -OC(O)aryl, -OC(O)C 1-10 Alkylaryl, -OC(O)C 2-10 Alkenylaryl, -OC(O)C 2-10 Alkynylaryl, -OC(O)C 1-10 Alkyl C(O)R 11 、-OC(O)C 2-10 Alkenyl C(O)R 11 、-OC(O)C 2-10 Alkynyl C(O)R 11 、-OC(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-OC(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-OC(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-OC(O)C 1-10 Alkyl SR 11 、-OC(O)C 2-10 Alkenyl SR 11 、-OC(O)C 2-10 Alkynyl SR 11 、-OC(O)C 1-10 Alkyl C(O)OR 11 、-OC(O)C 2-10 Alkenyl C(O)OR 11 、-OC(O)C 2-10 Alkynyl C(O)OR 11 、-OC(O)C 1-10 Alkyl C(O)SR 11 、-OC(O)C 2-10 Alkenyl C(O)SR 11 and -OC(O)C 2-10 Alkynyl C(O)SR 11 ; iii) R 4 and R 5 are each independently selected from H and –CH 3 ; iv) R 6 is hydrogen, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, –C(O)C 2-6 Alkynyl or -C(O)aryl; v)R 7 It is hydroxyl, -OC(O)C 1-6 Alkyl, -OC(O)C 2-6 Alkenyl or –OC(O)C 2-6 Alkynyl; and vi) R 8 is H or –CH 3 .

10. The method according to claim 9, wherein R 2 and R 3 Independently selected from -OC(O)C 1-20 Alkyl, -OC(O)C 2-20 Alkenyl, -OC(O)C 2-20 Alkynyl, -OC(O)cycloalkyl, -OC(O)C 1-10 Alkylcycloalkyl; -OC(O)C 2-10 Alkenylcycloalkyl, -OC(O)C 2-10 Alkynylcycloalkyl and -OC(O)aryl.

11. The method according to claim 9 or claim 10, wherein R 2 and R 3 Independently selected from -OC(O)C 1-20 Alkyl, -OC(O)C 2-20 Alkenyl and -OC(O)C 2-20 Alkynyl.

12. The method according to any one of claims 1 to 11, wherein the compound of formula (I) is a compound of formula (II): or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof; Where R 6 , R 7 and R 9 As defined in claim 1.

13. The method according to claim 1, wherein the epoxy croton terpene compound of formula (I) is selected from the following compounds: 12-crotonyl-13-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one; 12,13-di-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one; 12-hexanoyl-13-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one; 12,13-Dihexanoyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one; 12-Myristoyl-13-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one; 12-crotonyl-13-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13-pentahydroxy-20-acetoxy-1-crotonen-3-one; 12-myristoyl-13-acetoxy-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one; 12-Propionyl-13-(2-methylbutyryl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one; 12,13-Dicrotonyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one; and 12-(2-methylbutyryl)-13-crotonyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonen-3-one; or a pharmaceutically acceptable salt thereof.

14. The method of any one of claims 1 to 13, wherein the epoxycrotonane compound and the second therapeutic agent are administered separately and simultaneously.

15. The method according to any one of claims 1 to 14, wherein the tumor is a skin tumor or a subcutaneous tumor.

16. The method of any one of claims 1 to 15, wherein the tumor is a squamous cell carcinoma, an adenocarcinoma, or a sarcoma.

17. The method according to any one of claims 1 to 16, wherein the tumor is head or neck cancer.

18. The method of claim 16 or 17, wherein the tumor is a skin or mucosal squamous cell carcinoma.

19. The method according to any one of claims 1 to 18, wherein the epoxycroton terpene compound is (4S, 5S, 6R, 7S, 8R, 9R, 10S, 11R, 12R, 13S, 14R)-12-(2E)-2-methyl-2-enoyl-13((2S)-2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-crotonene-3-one.

20. The method of claim 19, wherein the second therapeutic agent is selected from cisplatin, 5-fluorouracil, doxorubicin, and radiation.

21. A combination of an epoxy croton terpene compound and a second therapeutic agent for use in treating tumors, wherein the epoxy croton terpene compound is a compound of formula (I): or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof; in R 1 is hydrogen or C 1-6 alkyl; R 2 Is -OH or –OR 9 ; R 3 Is -OH or –OR 9 ; R 4 and R 5 are independently selected from hydrogen and C 1-6 alkyl; R 6 is hydrogen or –R 10 ; R 7 is hydroxyl or OR 10 ; R 8 is hydrogen or C 1-6 alkyl; R 9 Yes-C 1-20 Alkyl, -C 2-20 Alkenyl, -C 2-20 Alkynyl, -C(O)C 1-20 Alkyl, -C(O)C 2-20 Alkenyl, -C(O)C 2-20 Alkynyl, -C(O)cycloalkyl, -C(O)C 1-10 Alkylcycloalkyl; -C(O)C 2-10 Alkenylcycloalkyl, -C(O)C 2-10 Alkynylcycloalkyl, -C(O)aryl, -C(O)C 1-10 Alkylaryl, -C(O)C 2-10 Alkenylaryl, -C(O)C 2-10 Alkynylaryl, -C(O)C 1-10 Alkyl C(O)R 11 、-C(O)C 2-10 Alkenyl C(O)R 11 、-C(O)C 2-10 Alkynyl C(O)R 11 、-C(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-C(O)C 1-10 Alkyl SR 11 、-C(O)C 2-10 Alkenyl SR 11 、-C(O)C 2-10 Alkynyl SR 11 、-C(O)C 1-10 Alkyl C(O)OR 11 、-C(O)C 2-10 Alkenyl C(O)OR 11 、-C(O)C 2-10 Alkynyl C(O)OR 11 、-C(O)C 1-10 Alkyl C(O)SR 11 、-C(O)C 2-10 Alkenyl C(O)SR 11 、-C(O)C 2-10 Alkynyl C(O)SR 11 , R 10 Yes-C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, -C(O)C 2-6 Alkynyl, -C(O)aryl, -C(O)C 1-6 Alkylaryl, -C(O)C 2-6 Alkenylaryl or -C(O)C 2-6 Alkynylaryl; and R 11 It is hydrogen, -C 1-10 Alkyl, -C 2-10 Alkenyl, -C 2-10 Alkynyl, cycloalkyl or aryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted; and wherein the second therapeutic agent is selected from: i) chemotherapeutic agents that damage DNA; ii) chemotherapeutic agents that inhibit tumor-associated host-derived cells that support tumor cell growth and / or invasion; and iii) Irradiation.

22. Use of an epoxy croton terpene compound in preparing a first drug and a second chemotherapeutic agent in preparing a second drug, wherein the first drug and the second drug are used as a combination therapy for treating tumors; wherein the epoxy croton terpene compound is a compound of formula (I): or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof; in R 1 is hydrogen or C 1-6 alkyl; R 2 Is -OH or –OR 9 ; R 3 Is -OH or –OR 9 ; R 4 and R 5 are independently selected from hydrogen and C 1-6 alkyl; R 6 is hydrogen or –R 10 ; R 7 is hydroxyl or OR 10 ; R 8 is hydrogen or C 1-6 alkyl; R 9 Yes-C 1-20 Alkyl, -C 2-20 Alkenyl, -C 2-20 Alkynyl, -C(O)C 1-20 Alkyl, -C(O)C 2-20 Alkenyl, -C(O)C 2-20 Alkynyl, -C(O)cycloalkyl, -C(O)C 1-10 Alkylcycloalkyl; -C(O)C 2-10 Alkenylcycloalkyl, -C(O)C 2-10 Alkynylcycloalkyl, -C(O)aryl, -C(O)C 1-10 Alkylaryl, -C(O)C 2-10 Alkenylaryl, -C(O)C 2-10 Alkynylaryl, -C(O)C 1-10 Alkyl C(O)R 11 、-C(O)C 2-10 Alkenyl C(O)R 11 、-C(O)C 2-10 Alkynyl C(O)R 11 、-C(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-C(O)C 1-10 Alkyl SR 11 、-C(O)C 2-10 Alkenyl SR 11 、-C(O)C 2-10 Alkynyl SR 11 、-C(O)C 1-10 Alkyl C(O)OR 11 、-C(O)C 2-10 Alkenyl C(O)OR 11 、-C(O)C 2-10 Alkynyl C(O)OR 11 、-C(O)C 1-10 Alkyl C(O)SR 11 、-C(O)C 2-10 Alkenyl C(O)SR 11 、-C(O)C 2-10 Alkynyl C(O)SR 11 , R 10 Yes-C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, -C(O)C 2-6 Alkynyl, -C(O)aryl, -C(O)C 1-6 Alkylaryl, -C(O)C 2-6 Alkenylaryl or -C(O)C 2-6 Alkynylaryl; and R 11 It is hydrogen, -C 1-10 Alkyl, -C 2-10 Alkenyl, -C 2-10 Alkynyl, cycloalkyl or aryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl is optionally substituted; and Wherein the second chemotherapeutic agent is selected from: i) chemotherapeutic agents that damage DNA; and ii) Chemotherapeutic agents that inhibit tumor-associated host-derived cells that support tumor cell growth and / or invasion.

23. Use of an epoxy croton terpene compound in the preparation of a medicament for treating tumors in combination therapy with irradiation; wherein the epoxy croton terpene compound is a compound of formula (I): or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof; in R 1 is hydrogen or C 1-6 alkyl; R 2 Is -OH or –OR 9 ; R 3 Is -OH or –OR 9 ; R 4 and R 5 are independently selected from hydrogen and C 1-6 alkyl; R 6 is hydrogen or –R 10 ; R 7 is hydroxyl or OR 10 ; R 8 is hydrogen or C 1-6 alkyl; R 9 Yes-C 1-20 Alkyl, -C 2-20 Alkenyl, -C 2-20 Alkynyl, -C(O)C 1-20 Alkyl, -C(O)C 2-20 Alkenyl, -C(O)C 2-20 Alkynyl, -C(O)cycloalkyl, -C(O)C 1-10 Alkylcycloalkyl; -C(O)C 2-10 Alkenylcycloalkyl, -C(O)C 2-10 Alkynylcycloalkyl, -C(O)aryl, -C(O)C 1-10 Alkylaryl, -C(O)C 2-10 Alkenylaryl, -C(O)C 2-10 Alkynylaryl, -C(O)C 1-10 Alkyl C(O)R 11 、-C(O)C 2-10 Alkenyl C(O)R 11 、-C(O)C 2-10 Alkynyl C(O)R 11 、-C(O)C 1-10 Alkyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkenyl CH(OR 11 )(OR 11 )、-C(O)C 2-10 Alkynyl CH(OR 11 )(OR 11 )、-C(O)C 1-10 Alkyl SR 11 、-C(O)C 2-10 Alkenyl SR 11 、-C(O)C 2-10 Alkynyl SR 11 、-C(O)C 1-10 Alkyl C(O)OR 11 、-C(O)C 2-10 Alkenyl C(O)OR 11 、-C(O)C 2-10 Alkynyl C(O)OR 11 、-C(O)C 1-10 Alkyl C(O)SR 11 、-C(O)C 2-10 Alkenyl C(O)SR 11 、-C(O)C 2-10 Alkynyl C(O)SR 11 , R 10 Yes-C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C(O)C 1-6 Alkyl, -C(O)C 2-6 Alkenyl, -C(O)C 2-6 Alkynyl, -C(O)aryl, -C(O)C 1-6 Alkylaryl, -C(O)C 2-6 Alkenylaryl or -C(O)C 2-6 Alkynylaryl; and R 11 It is hydrogen, -C 1-10 Alkyl, -C 2-10 Alkenyl, -C 2-10 Alkynyl, cycloalkyl or aryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is optionally substituted.